FOR INCREASED PROTEIN PRODUCTION

CROSS REFERENCE TO REUATED APPUICATIONS

[0001] This application claims benefit to U.S. Provisional Application No. 62/613,339, filed January 03, 2018, which is hereby incorporated by referenced in its entirety.

FIEUD

[0002] The present disclosure is generally related to the fields of bacteriology, microbiology, genetics, molecular biology, enzymology, industrial protein production and the like. More particularly, certain embodiments of the disclosure are related to novel Bacillus sp. mutants capable of producing increased amounts of industrially relevant proteins of interest. Other embodiments of the disclosure are related to modified Bacillus sp. cells comprising an introduced polynucleotide encoding a variant GlcT protein. Other embodiments are related to methods and compositions for producing endogenous and/or heterologous proteins of interest in the modified Bacillus sp. (daughter) cells, whereas certain other embodiments are directed to nucleic acid sequences, particularly polynucleotide open reading frame (ORF) sequences, vectors thereof and DNA expression constructs thereof, encoding variant GlcT proteins of the disclosure.

REFERENCE TO A SEQUENCE FISTING

[0003] The contents of the electronic submission of the text file Sequence Listing, named “NB4l30l_WO_PCT_SEQ.txt” was created on December 11, 2018 and is 137 KB in size, which is hereby incorporated by reference in its entirety.

BACKGROUND

[0004] Gram-positive bacteria such as Bacillus subtilis, Bacillus licheniformis, Bacillus amyloliquefaciens and the like are frequently used as microbial factories for the production of industrial relevant proteins, due to their excellent fermentation properties and high yields (e.g., up to 25 grams per liter culture; Van Dijl and Hecker, 2013). For example, B. subtilis is well known for its production of a-amylases (Jensen el al, 2000; Raul et al., 2014) and proteases (Brode el al, 1996) necessary for food, textile, laundry, medical instrument cleaning, pharmaceutical industries and the like (Westers et al, 2004). Because these non- pathogenic Gram-positive bacteria produce proteins that completely lack toxic by-products (e.g., lipopolysaccharides; LPS, also known as endotoxins) they have obtained the“Qualified Presumption of Safety” (QPS) status of the European Food Safety Authority, and many of their products gained a “Generally Recognized as Safe” (GRAS) status from the US Food and Drug Administration (Olempska- Beer et al., 2006; Earl et al, 2008; Caspers et al., 2010).

[0005] Thus, the production of proteins (e.g., enzymes, antibodies, receptors, etc.) in microbial host cells is of particular interest in the biotechnological arts. Likewise, the optimization of Bacillus host cells for the production and secretion of one or more protein(s) of interest is of high relevance, particularly in the industrial biotechnology setting, wherein small improvements in protein yield are quite significant when the protein is produced in large industrial quantities. More particularly, B. licheniformis and B. subtilis are exemplary Bacillus sp. host cells of high industrial importance, and as such, the ability to genetically modify and engineer Bacillus sp. host cells for enhanced/increased protein expression/production is highly desirable for construction of new and improved Bacillus sp. production strains. Thus, the disclosure set forth herein is related to the highly desirable and unmet needs of obtaining and constructing Bacillus host cells (e.g., protein production host cells, cell factories) having increased protein production capabilities, increased secondary metabolite production, and the like.

SUMMARY

[0006] The instant disclosure is generally related to compositions and methods for producing and constructing Bacillus sp. (host) cells (e.g., protein production host cells, cell factories) having increased protein production capabilities, increased secondary metabolite production capabilities and the like.

[0007] More particularly, certain embodiments of the disclosure are related to a mutant of a parental Bacillus licheniformis cell comprising a glcT gene encoding a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. In certain embodiments, the gene encoding the variant GlcT protein of SEQ ID NO: 55 comprises a nucleic acid sequence comprising at least 90% sequence identity to SEQ ID NO 22, SEQ ID NO: 81 or SEQ ID NO: 56. In other embodiments, the mutant B. licheniformis cell further comprises a restored rghR2 gene (rghR2 _{KS t} ) encoding a RghR2 protein of SEQ ID NO: 84. In other embodiments, the mutant cell comprises an introduced polynucleotide encoding a protein of interest (POI). In certain embodiments, the POI is an amylase or a protease. In other embodiments, the introduced polynucleotide encoding the POI comprises a mod-5 '-UTR sequence of SEQ ID NO: 63 operably linked and upstream (5') of the polynucleotide encoding the POI.

[0008] In other embodiments, the disclosure is related to a genetically modified Bacillus cell derived from a parental Bacillus cell comprising a wild-type glcT gene encoding a wild-type GlcT protein of SEQ ID NO: 82, wherein the modified Bacillus cell comprises a modified glcT gene encoding a GlcT protein comprising at least 90% sequence identity to SEQ ID NO: 55 and comprising a phenylalanine (F) at position 67 of SEQ ID NO: 55. In certain embodiments, the wild-type glcT gene encoding the wild-type GlcT protein of SEQ ID NO: 82 in the parental cell is modified with a glcT-Cas9 targeting vector, wherein the glcT- Cas9 targeting vector modifies codon 67 of the wild-type glcT gene, wherein modified glcT gene encodes a GlcT protein comprising at least 90% sequence identity to SEQ ID NO: 55 and comprising a phenylalanine (F) at position 67 of SEQ ID NO: 55.

[0009] Thus, in other embodiments, the disclosure is related to a genetically modified Bacillus cell comprising an introduced polynucleotide encoding a variant GlcT protein comprising at least 90% sequence identity to SEQ ID NO: 55 and comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. In certain embodiments, The modified cell further comprises an inactivated endogenous chromosomal glcT gene encoding a GlcT protein comprising at least 90% sequence identity to SEQ ID NO: 82 and comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82. In other embodiments, the modified Bacillus cell is a Bacillus licheniformis cell, wherein the modified B. licheniformis further comprises a restored rghR2 gene (rghR2 _{K l} ) encoding a RghR2 protein of SEQ ID NO: 84. In related embodiments, the modified cell of the disclosure comprises an introduced polynucleotide encoding a heterologous POI. In certain embodiments, the POI is an amylase or a protease. In another embodiment, the introduced polynucleotide integrates into a targeted Bacillus cell chromosomal gene locus. In certain other embodiments, the introduced polynucleotide encoding the POI comprises a mod-5 '-UTR sequence of SEQ ID NO: 63 operably linked and upstream (5') of the polynucleotide sequence encoding the POI.

[0010] In other embodiments, the disclosure is related to a modified Bacillus cell derived from a parental Bacillus cell comprising a glcT gene encoding a wild-type GlcT protein comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82, wherein the modified Bacillus cell comprises a modified glcT gene encoding a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55, wherein the modified Bacillus cell produces an increased amount of a protein of interest (POI) relative to the parental cell producing the same POI. Thus, in certain embodiments, the modified cell comprises an introduced DNA construct encoding a heterologous POI, wherein the modified Bacillus cell produces an increased amount of the heterologous POI relative to the parental cell producing the same heterologous POI. In other embodiments, the modified cell further comprises a restored rghR2 gene encoding a RghR2 protein of SEQ ID NO: 84. In certain embodiments, the POI is an amylase or a protease. In certain other embodiments, the introduced DNA construct encoding the POI comprises a modified 5'- UTR sequence of SEQ ID NO: 63 operably linked upstream (5') of the DNA construct.

[0011] In other embodiments, the disclosure is related to an isolated polynucleotide open reading frame (ORF) encoding a variant Bacillus sp. GlcT (anti-termination) protein, the variant GlcT protein comprising a leucine (L) to phenylalanine (F) substitution at amino acid position 67 (L67F) of SEQ ID NO: 55. In certain embodiments, the variant protein comprises 95% or greater sequence identity to SEQ ID NO: 55 and comprises a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. In other embodiments, the ORF comprises a nucleic acid sequence having at least 95% sequence identity to SEQ ID NO: 56.

[0012] Thus, certain embodiments are related to a vector comprising a polynucleotide encoding a variant GlcT protein of SEQ ID NO: 55. In other embodiments, the vector comprises an upstream (5') homology region (5'-HR) operably linked (5') to the ORF sequence and/or a downstream (3') homology region (3'- HR) operably linked (3') to the ORF sequence, wherein the 5'-HR and/or the 3'-HR comprise(s) sufficient homology with a targeted genomic locus of a Bacillus sp. host cell to effect integration of the vector into the targeted genomic locus by homologous recombination, when the vector is transformed into a competent Bacillus sp. host cell.

[0013] In other embodiments, the disclosure is related to an expression construct comprising a polynucleotide ORF encoding a variant GlcT protein of SEQ ID NO: 55. In certain embodiments, the construct comprises a promoter nucleic acid sequence functional in Bacillus sp. cells, wherein the promoter sequence is operably linked and upstream (5') of the ORF sequence. In other embodiments, the construct further comprises a modified B. subtilis aprE 5 '-untranslated region sequence (5'-UTR) of SEQ ID NO: 63, wherein the modified 5'-UTR is downstream (3') and operably linked to the promoter sequence and upstream (5 ') and operably linked to the ORF sequence . In certain other embodiments, the construct further comprises a terminator sequence downstream (3') and operably linked to the ORF sequence.

[0014] In other embodiments, the disclosure is related to a method for producing increased amounts of a protein of interest (POI) in a mutant of a parental Bacillus licheniformis cell comprising (a) obtaining a mutant of a parental B. licheniformis cell comprising a glcT gene encoding a GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55 and introducing into the mutant cell a polynucleotide construct encoding a heterologous POI, (b) cultivating the mutant cell of step (a) in a medium suitable for the production of a POI, and (c) recovering the POI from the cultivation medium, wherein the mutant B. licheniformis cell produces an increased amount of the POI relative to the parental B. licheniformis cell producing the same POI, when cultivated under the same conditions.

[0015] Other embodiments are related to a method for producing increased amounts of a protein of interest (POI) in a modified Bacillus cell derived from an unmodified Bacillus parental cell comprising (a) obtaining a parental Bacillus cell comprising an endogenous chromosomal glcT gene encoding a wild-type GlcT protein comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82 and modifying the parental cell by introducing (i) a polynucleotide encoding a variant GlcT protein comprising at least 90% sequence identity to SEQ ID NO: 55 and comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55 and (ii) a polynucleotide encoding a POI, (b) cultivating the modified cell of step (a) in a medium suitable for the production of a POI, and (c) recovering the POI from the cultivation medium, wherein the modified Bacillus cell produces an increased amount of the POI relative to the parental cell producing the same POI when cultivated under the same conditions. In certain other embodiments, the introduced polynucleotide encoding the GlcT variant protein integrates into the chromosomal glcT gene locus by homologous recombination, thereby replacing and eliminating the endogenous chromosomal glcT gene encoding the GlcT protein of SEQ ID NO: 82.

[0016] In another embodiment, the disclosure is related to a method for producing increased amounts of a protein of interest (POI) in a modified Bacillus cell derived from an unmodified Bacillus parental cell comprising (a) obtaining a parental Bacillus cell comprising an endogenous chromosomal glcT gene encoding a wild-type GlcT protein comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82, (b) modifying the parental cell of step (a) w ith ay/c7 ^' -Cas9 targeting vector, wherein the glcT-Cas9 targeting vector modifies codon 67 of the wild-type glcT gene, wherein modified glcT gene encodes a GlcT protein comprising at least 90% sequence identity to SEQ ID NO: 55 and comprising a phenylalanine (F) at position 67 of SEQ ID NO: 55, (c) cultivating the modified cell of step (b) in a medium suitable for the production of a POI, and (c) recovering the POI from the cultivation medium, wherein the modified Bacillus cell produces an increased amount of the POI relative to the parental cell producing the same POI when cultivated under the same conditions. In certain embodiments, n the POI is an endogenous POI or a heterologous POI. In particular embodiments, the POI is a heterologous POI.

BRIEF DESCRIPTION OF DRAWINGS

[0017] Figure 1 presents a nucleic acid sequence alignment (FIG. 1A) and an amino acid sequence alignment (FIG. IB) of glcT wild-type (SEQ ID NO: 22) and glcT mutant (SEQ ID NO: 56) nucleic acid sequences, encoding GlcT wild-type (SEQ ID NO: 82) and GlcT variant (SEQ ID NO: 55) protein sequences, respectively. More particularly, FIG. 1A shows a nucleic acid sequence alignment of a B. licheniformis ORF (SEQ ID NO: 22) encoding a wild-type GlcT protein (SEQ ID NO: 82) relative to a mutant B. licheniformis ORF (SEQ ID NO: 56) encoding a variant GlcT protein (SEQ ID NO: 55). For example, as shown in FIG. 1A, the two aligned ORF sequences (SEQ ID NO: 22 vs. SEQ ID NO: 56) differ by a single nucleotide polymorphism (SNP) at nucleotide position 199, wherein position 199 of SEQ ID NO: 22 comprises a cytosine (C) and position 199 of SEQ ID NO: 56 comprises a thymine (T); e.g., see FIG. 1A black boxed nucleotides (C) and (T) at position 199). Similarly, FIG. IB shows an alignment of the encoded wild-type GlcT protein (SEQ ID NO: 82) and the encoded variant GlcT protein (SEQ ID NO: 55), wherein the (C) to (T) SNP at position 199 of SEQ ID NO: 56 (see, FIG. 1A), results in a leucine (L) to phenylalanine (F) substitution at amino acid residue position 67 of SEQ ID NO: 55 (e.g., see FIG. IB, black boxed (L) and (F) amino acids at residue position 67 of SEQ ID NO: 22 and SEQ ID NO: 55, respectively). [0018] Figure 2 shows normalized a-amylase Ceralpha activity (FIG. 2A) and a-amylase specific productivity (FIG. 2B) in microtiter plates, wherein Bacillus host cells BF117 (WT glcT + mod-5 '-UTR), BF134 (WT glcT + WT-5'-UTR), HM150-1 (variant glcTl + mod-5'-UTR) and HM151 (variant glcTl + WT-5'-UTR) were screened. As presented in FIG. 2B, the normalized a-amylase Qp of host cell HM151 (variant glcTl + WT-5'-UTR) is approximately 4-5% increased relative to the a-amylase Qp of either host cell BF134 (WT glcT + WT-5'-UTR) or BF117 (WT glcT + mod-5'-UTR). Furthermore, as presented in FIG. 2B, the a-amylase Qp of Bacillus host cell HM150-1 (variant glcTl + mod-5'-UTR) is approximately 9% increased relative to the a-amylase Qp of either host cell BF134 (WT glcT + WT-5'-UTR) or BF117 (WT glcT + mod-5'-UTR), and approximately 4-5% increased relative to the a-amylase Qp of host cell HM151 (variant glcTl + WT-5'-UTR).

BRIEF DESCRIPTION OF THE BIOLOGICAL SEQUENCES

[0019] SEQ ID NO: 1 is a synthetic nucleic acid sequence encoding a Cas9 protein.

[0020] SEQ ID NO: 2 is an amino acid sequence of an N-terminal Nuclear Localization Signal (NLS) sequence.

[0021] SEQ ID NO: 3 is an amino acid sequence of a C-terminal NLS sequence.

[0022] SEQ ID NO: 4 is an amino acid sequence comprising a rieco-histidine (10-H) tag.

[0023] SEQ ID NO: 5 is a nucleic acid sequence comprising a B. subtilis aprE promoter.

[0024] SEQ ID NO: 6 is an Cas9 forward primer nucleic acid sequence.

[0025] SEQ ID NO: 7 is an Cas9 reverse primer nucleic acid sequence.

[0026] SEQ ID NO: 8 is a nucleic acid sequence of plasmid pKB320 backbone.

[0027] SEQ ID NO: 9 is a nucleic acid sequence of plasmid pKB320.

[0028] SEQ ID NO: 10 is a pKB320 forward primer nucleic acid sequence.

[0029] SEQ ID NO: 11 is a pKB320 reverse primer nucleic acid sequence.

[0030] SEQ ID NO: 12 is a Cas9“reverse sequencing primer 1” nucleic acid sequence.

[0031] SEQ ID NO: 13 is a Cas9“reverse sequencing primer 2” nucleic acid sequence.

[0032] SEQ ID NO: 14 is a Cas9“forward sequencing primer 1” nucleic acid sequence.

[0033] SEQ ID NO: 15 is a Cas9“forward sequencing primer 2” nucleic acid sequence.

[0034] SEQ ID NO: 16 is a Cas9“forward sequencing primer 3” nucleic acid sequence.

[0035] SEQ ID NO: 17 is a Cas9“forward sequencing primer 4” nucleic acid sequence.

[0036] SEQ ID NO: 18 is a Cas9“forward sequencing primer 5” nucleic acid sequence.

[0037] SEQ ID NO: 19 is a Cas9“forward sequencing primer 6” nucleic acid sequence.

[0038] SEQ ID NO: 20 is a Cas9“forward sequencing primer 7” nucleic acid sequence. [0039] SEQ ID NO: 21 is a nucleic acid sequence of pRF694.

[0040] SEQ ID NO: 22 is a Bacillus licheniformis wild-type glcT ORF sequence.

[0041] SEQ ID NO: 23 is a nucleic acid sequence of a B. licheniformis glcT gene target site.

[0042] SEQ ID NO: 24 is a synthetic nucleic acid sequence encoding glcTY T domain.

[0043] SEQ ID NO: 25 (AGG) is a three nucleotide PAM sequence of a B. licheniformis glcT target site.

[0044] SEQ ID NO: 26 is a synthetic nucleic acid sequence encoding Cas9 endonuclease recognition domain.

[0045] SEQ ID NO: 27 is a synthetic RNA sequence comprising a glcT guide-RNA (gRNA) nucleic acid sequence

[0046] SEQ ID NO: 28 is a synthetic DNA sequence encoding a glcT gRNA.

[0047] SEQ ID NO: 29 is a Bacillus suhtilis nucleic acid sequence comprising a rrnlp2 promoter sequence.

[0048] SEQ ID NO: 30 is a lambda phage tO terminator nucleic acid sequence.

[0049] SEQ ID NO: 31 is a nucleic acid sequence comprising a glcT gRNA expression cassette.

[0050] SEQ ID NO: 32 is a B. licheniformis nucleic acid sequence comprising a 500 bp (homology arm) which is upstream (5') of nucleotide position 199 encoding a leucine (L) at amino acid residue position 67 (L67).

[0051] SEQ ID NO: 33 is a glcT 5' forward primer nucleic acid sequence.

[0052] SEQ ID NO: 34 is a. glcT 5' reverse primer nucleic acid sequence.

[0053] SEQ ID NO: 35 is a B. licheniformis nucleic acid sequence comprising a 500 bp (homology arm) which is downstream (3 ¹ ) of nucleotide position 199 encoding a leucine (L) at amino acid residue position 67 (L67).

[0054] SEQ ID NO: 36 is a glcT 3' forward primer nucleic acid sequence.

[0055] SEQ ID NO: 37 is a glcT 3' reverse primer nucleic acid sequence.

[0056] SEQ ID NO: 38 is a nucleic acid sequence of pRF731.

[0057] SEQ ID NO: 39 is a nucleic acid sequence of pEF724.

[0058] SEQ ID NO: 40 is a B. licheniformis nucleic acid sequence comprising a duplication of rghR2 gene codons 24-29.

[0059] SEQ ID NO: 41 is a B. licheniformis rghR2 nucleic acid sequence comprising a rghR2gene with duplication

[0060] SEQ ID NO: 42 is an 8.3kb PCR product of pRF694.

[0061] SEQ ID NO: 43 is a pRF694 forward primer.

[0062] SEQ ID NO: 44 is a pRF694 reverse primer.

[0063] SEQ ID NO: 45 is a synthetic rghR2 editing template gRNA cassette. [0064] SEQ ID NO: 46 is a synthetic rghR2 nucleic acid sequence editing template.

[0065] SEQ ID NO: 47 is a rghR2 gRNA expression cassette.

[0066] SEQ ID NO: 48 is a rghR2 cassette forward primer.

[0067] SEQ ID NO: 49 is a rghR2 cassette reverse primer.

[0068] SEQ ID NO: 50 is a nucleic acid sequence comprising plasmid pBL. comK.

[0069] SEQ ID NO: 51 is a B. licheniformis glcT gene locus.

[0070] SEQ ID NO: 52 is a synthetic glcT locus forward primer.

[0071] SEQ ID NO: 53 is a synthetic glcT locus reverse primer.

[0072] SEQ ID NO: 54 is a synthetic glcT locus forward sequencing primer.

[0073] SEQ ID NO: 55 is an amino acid sequence of the variant GlcT (L67F) protein encoded by the glcT ORF of SEQ ID NO: 56.

[0074] SEQ ID NO: 56 is a synthetic nucleic acid sequence comprising a mutant glcT ORF (C199T) encoding the variant GlcT (L67F) protein of SEQ ID NO: 55.

[0075] SEQ ID NO: 57 is a B. licheniformis nucleic acid sequence comprising a rghr2 locus.

[0076] SEQ ID NO: 58 is a synthetic rghRl locus forward primer.

[0077] SEQ ID NO: 59 is a synthetic rghRl locus reverse primer.

[0078] SEQ ID NO: 60 is a synthetic rghR2 locus sequencing primer.

[0079] SEQ ID NO: 61 is a B. licheniformis nucleic acid sequence comprising a rghR2 restored locus.

[0080] SEQ ID NO: 62 is a B. suhtilis nucleic acid sequence comprising an aprE 5'-UTR.

[0081] SEQ ID NO: 63 is a synthetic nucleic acid sequence comprising a modified aprE 5'-UTR, referred to hereinafter as“ aprE mod-5 ¹ UTR”

[0082] SEQ ID NO: 64 is a synthetic nucleic acid sequence comprising a wild-type 5'-UTR (WT 5'-UTR) expression construct.

[0083] SEQ ID NO: 65 is a synthetic nucleic acid sequence comprising a modified 5'-UTR expression construct.

[0084] SEQ ID NO: 66 is a B. licheniformis nucleic acid sequence comprising a 5' catH homology arm.

[0085] SEQ ID NO: 67 is a B. licheniformis nucleic acid sequence comprising a catH gene.

[0086] SEQ ID NO: 68 is a synthetic nucleic acid sequence comprising a spoVGrrnlp hybrid promoter.

[0087] SEQ ID NO: 69 is a B. licheniformis nucleic acid sequence comprising a lat signal sequence.

[0088] SEQ ID NO: 70 is a G. stearothermophilus nucleic acid sequence encoding variant G. stearothermophilus a-amylase.

[0089] SEQ ID NO: 71 is a B. licheniformis nucleic acid sequence comprising a lat terminator.

[0090] SEQ ID NO: 72 is a B. licheniformis nucleic acid sequence comprising a 3' catH homology arm.

[0091] SEQ ID NO: 73 is an amino acid sequence of a variant G. stearothermophilus a-amylase. [0092] SEQ ID NO: 74 is a synthetic nucleic acid sequence comprising a wild-type catH locus construct.

[0093] SEQ ID NO: 75 is a synthetic nucleic acid sequence comprising a modified 5'-UTR catH locus construct.

[0094] SEQ ID NO: 76 is a synthetic catH locus forward primer.

[0095] SEQ ID NO: 77 is a synthetic catH locus reverse primer.

[0096] SEQ ID NO: 78 is a synthetic catH forward sequencing primer 1.

[0097] SEQ ID NO: 79 is a synthetic catH forward sequencing primer 2.

[0098] SEQ ID NO: 80 is a synthetic catH forward sequencing primer 3.

[0099] SEQ ID NO: 81 is nucleic acid sequence comprising a B. licheniformis wild-type glcT gene, encoding a wild-type GlcT protein of SEQ ID NO: 82.

[0100] SEQ ID NO: 82 is the amino acid sequence of a B. licheniformis wild-type GlcT protein, encoded by a B. licheniformis glcT ORF of SEQ ID NO: 22 or a B. licheniformis glcT gene of SEQ ID NO: 81.

[0101] SEQ ID NO: 83 is the amino acid sequence of a B. licheniformis variant RghR2 protein comprising a repeat (duplication) of six amino acids (AAAISR): A32A33A34I35S36R37-A38A39A40I41S42R43.

[0102] SEQ ID NO: 84 is the amino acid sequence of a restored (native) B. licheniformis RghR2 protein.

DETAILED DESCRIPTION

[0103] The instant disclosure is generally related to compositions and methods for producing and constructing Bacillus sp. (host) cells (e.g., protein production host cells, cell factories) having increased protein production capabilities, increased secondary metabolite production capabilities and the like. More particularly, certain embodiments of the disclosure are directed to mutant Bacillus sp. cells comprising a glcT gene encoding a variant GlcT (transcriptional anti-termination) protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. Certain other embodiments are related to genetically modified Bacillus sp. cells comprising an introduced polynucleotide encoding a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55.

[0104] Other embodiments of the disclosure are directed to modified Bacillus sp. cells comprising an edited (modified) glcT gene encoding a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. For example, certain embodiments of the disclosure (Example 2) are related to glcT Cas9 targeting vectors and modified Bacillus cells thereof comprising a Cas9 edited (modified) glcT gene encoding a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55.

[0105] In certain other embodiments, the disclosure is related to modified Bacillus (daughter) cells comprising an inactivated (endogenous) native chromosomal glcT gene (i.e., encoding a wild-type GlcT protein comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82) and comprising an introduced polynucleotide encoding a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. Thus, in certain embodiments, the disclosure is related to such modified Bacillus cells (e.g., comprising a modified glcT gene encoding a GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55), wherein the modified Bacillus cells produce an increased amount of a protein of interest (POI) relative to the parental cell from which they were derived (i.e.. expressing/producing the same POI).

[0106] In certain other embodiments, the disclosure is directed to an isolated polynucleotide comprising an open reading frame (ORF) encoding a variant Bacillus sp. GlcT (anti-termination) protein, the variant GlcT protein comprising a leucine (L) to phenylalanine (F) substitution at amino acid position 67 (L67F) of SEQ ID NO: 55. In related embodiments, the polynucleotide ORF encodes a variant GlcT protein comprising at least about 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 55 or SEQ ID NO: 82, and comprises a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. In another embodiment, the polynucleotide comprises a nucleic acid sequence having at least about 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 22, SEQ ID NO: 81 or SEQ ID NO: 56, wherein the polynucleotide encodes a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55.

[0107] In other embodiments, the disclosure is related to a vector, a DNA expression construct and the like, comprising a polynucleotide encoding a variant GlcT protein of the disclosure. For example, in certain embodiments, a vector comprising an ORF encoding a variant GlcT protein, further comprises an upstream (5') homology region (5 '-HR) operably linked (5') to the ORF sequence and/or a downstream (3') homology region (3'-HR) operably linked (3') to the ORF sequence, wherein the 5'-HR and/or the 3'-HR comprise(s) sufficient homology with a targeted genomic locus of a Bacillus (host) cell to effect integration of the vector into the targeted genomic locus by homologous recombination (i.e.. when the vector is transformed into a competent Bacillus cell). For example, in certain embodiments, such vectors are introduced into a parental Bacillus cell comprising a glcT gene having an open reading frame (ORF) encoding a wild-type GlcT protein of SEQ ID NO: 82 (i.e., comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82), wherein the introduced vector comprises an ORF encoding the variant GlcT protein of SEQ ID NO: 55 (i.e., comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55), flanked by a 5'- HR and/or 3 '-HR comprising sufficient homology to the parental Bacillus (endogenous) nucleic acid sequence immediately upstream (5') and/or immediately downstream (3') of the glcT gene ORF chromosomal locus, to effect integration of the vector by homologous recombination, thereby deleting the ORF encoding the GlcT protein of SEQ ID NO: 82 and replacing the ORF encoding the GlcT protein of SEQ ID NO: 55. [0108] Thus, as set forth above, certain embodiments of the disclosure are related to such genetically modified Bacillus (daughter) cells producing increased amounts of one or more proteins of interest (i.e., relative to the Bacillus parental cells producing the same protein of interest, wherein the daughter and parental cells are cultivated under similar conditions). More particularly, as described in the Examples section of the disclosure (e.g., see, Example 1), Applicant performed routine NTG mutagenesis to create a pool of B. licheniformis mutants {i.e.. Bacillus daughter cells), which NTG modified (mutant) daughter cells were subsequently screened to identify B. licheniformis (mutant) daughter cell mutations that can increase the production of industrially relevant proteins of interest (e.g., an amylase, a protease, etc.). As presented in Example 1, a particular B. licheniformis (mutant) daughter cell capable of producing increased amounts of amylase protein was identified, wherein the (mutant) daughter cell differed from its parent by a single nucleotide polymorphism (SNP) in a gene encoding a variant GlcT protein. More particularly, the parental B. licheniformis cell comprises a glcT gene encoding a wild-type GlcT protein of SEQ ID NO: 82 (comprising a Leucine (L) amino acid at position 67 of SEQ ID NO: 82), whereas the B. licheniformis (mutant) daughter cell comprises a glcT gene encoding a variant GlcT protein of SEQ ID NO: 55 (comprising a Phenylalanine (F) amino acid at position 67 of SEQ ID NO: 55).

[0109] Furthermore, as presented in Example 2, Applicant constructed certain glcT Cas9 targeting vectors which change the first position of codon 67 from CTC to TTC (i.e., codon 67 of the glcT gene), thereby converting codon 67 from a Leucine (L) to a Phenylalanine (F). As presented and described in Example 3, such glcT Cas9 targeting vectors were transformed into competent (parental) B. licheniformis cells to generate and select modified B. licheniformis (daughter) cells comprising the Cas9 edited glcT gene, which modified cells thereby encode the variant GlcT protein comprising the L67F substitution. For example, as set forth in Example 3, sequence alignments comparing the sequencing data to the wild-type glcT locus revealed that some of the recovered colonies contained the desired genome edit causing the L67F mutation in the GlcT protein (SEQ ID NO: 55). More specifically, a B. licheniformis colony containing the modified/edited glcT gene (SEQ ID NO: 56) encoding the L67F GlcT protein (SEQ ID NO: 55), referred to herein as allele“ glcTT was stored as strain BF63 (glcTl pBL.comK).

[0110] In certain other embodiments, a modified Bacillus licheniformis (daughter) cell of the disclosure, comprising a modified glcT gene (e.g., allele glcTl) encoding a variant GlcT protein, further comprises a genetic modification which restores a mutated/variant rghr2 gene. For example, Applicant’s pending U.S. Provisional Patent Application Serial No. 62/463,268, filed February 24, 2017 (incorporated herein by reference in its entirety), fully describes such modified B. licheniformis (host) cells comprising a restored rghr2 gene (hereinafter, rghr2 _K f) and methods for producing the same. More particularly, as described in the above-referenced Provisional Application, the genomes of certain B. licheniformis strains/host cells were sequenced, which revealed that these sequenced strains comprise a duplication (i.e.. a repeat) of 18 nucleotides (l8-bp) in the rghr2 gene, wherein this 18-nucleotide (repeat) sequence encodes amino acids “AAAISR”, such that the variant RghR2 protein comprises a repeat of the AAAISR amino acid sequence (i.e., AAAISR- AAAISR). Furthermore, as described in the above -referenced Application, B. licheniformis (daughter) cells which were genetically modified to remove the l8-bp duplication (referred to as rghr2 _msi ) were capable of producing increased amounts of industrially relevant proteins in comparison (vis-a-vis) to the parental B. licheniformis cells comprising the l8-bp duplication (un-restored rghr2).

[0111] Thus, in certain embodiments, a modified Bacillus licheniformis cell of the disclosure comprises a modified glcT gene encoding a variant GlcT protein. In certain other embodiments, a modified Bacillus licheniformis cell of the disclosure comprises a modified glcT gene and a modified rghr2 gene (i.e.. rghr2 ^). More particularly, as presented in Examples 4-6 of the disclosure, Applicant further constructed rghr2 Cas9 targeting vectors (Example 4), and generated modified Bacillus licheniformis (daughter) cells comprising a restored rghr2 allele (i.e., rghr2 _ms Example 5, BF62 cell) and modified Bacillus (daughter) cells comprising a restored rghr2 allele and a modified glcT allele (i.e., rghr2 _KSt and modified glcT allele; Example 6, BF169 cell).

[0112] As described in Example 7 of the disclosure, heterologous a-amylase expression cassettes were introduced into parental and modified B. licheniformis (daughter) cells BF62, BF63 and BF169 (e.g, see, Table 17). More specifically, the a-amylase expression cassettes presented in Example 7 were constructed to additionally test the effect of an operably linked“wild-type-5 '-UTR sequence” versus an operably linked “modified-5'-UTR sequence” on the expression/production of the heterologous a-amylase. Thus, the a- amylase expression cassettes comprised either a wild-type B. subtilis aprE 5'-UTR (SEQ ID NO: 62) or a modified-5 '-UTR (SEQ ID NO: 63) operably linked to an upstream (5') promoter and a downstream (3') open reading frame encoding the a-amylase. Thus, the parental and modified B. licheniformis cells constructed in Example 7 (comprising and expressing a heterologous a-amylase expression cassette), were screened for the production of a-amylase in Example 8.

[0113] As presented in Example 8 (Table 18), the following B. licheniformis cells were screened for a- amylase production: (i) a B. licheniformis cell comprising an introduced “WT-5'-UTR a-amylase expression cassette” (SEQ ID NO: 62), referred to herein as strain/cell“BF134”, (ii) a B. licheniformis cell comprising an introduced“modified-5'-UTR a-amylase expression cassette” (SEQ ID NO: 63), referred to herein as strain/cell“BF117”, (iii) a B. licheniformis cell comprising allele glcTl and an introduced“WT- 5'-UTR a-amylase expression cassette” (SEQ ID NO: 62), referred to herein as strain/cell“HM151” and (iv) a B. licheniformis cell comprising allele glcTl and an introduced“modified-5'-UTR a-amylase expression cassette” (SEQ ID NO: 63), referred to herein as strain/cell ΉM150-1”. Furthermore, as presented in FIG. 2A and FIG. 2B, there is a significant increase in a-amylase activity and specific productivity from the Bacillus host cells comprising allele glcTl (i.e.. HM150-1 and HM151 cells) relative to the Bacillus host cells comprising the wild-type glcT gene (i.e., BF117 and BF134 cells).

[0114] As stated briefly above, certain other embodiments of the disclosure are related to modified Bacillus licheniformis cells comprising allele glcTl and further comprising a restored rghr2 gene ( rghr2 _KSi ). For example, as presented in Example 9 of the disclosure, modified Bacillus cells BF 118 ( rghr2 _KSt + mod-5 UTR amylase cassette), BF171 (rghr2 _msi + glcTl + mod-5 '-UTR amylase cassette), BF169 (rghr2 _K + WT- 5'-UTR amylase cassette) and BF260 ( rghr2 _KSi + glcTl + WT-5'-UTR amylase cassette) were screened for amylase production at small scale, wherein the relative amylase production of Bacillus cells BF171 and BF260 were significantly increased compared to the amylase production of Bacillus cells BF118 and BF169.

[0115] Thus, in certain other embodiments the disclosure is related to DNA expression constructs comprising an ORF of the disclosure, wherein the DNA construct further comprises a promoter nucleic acid sequence functional in Bacillus sp. cells, wherein the promoter sequence is operably linked and upstream (5') of the ORF sequence. In certain embodiments, the DNA construct further comprises a modified B. subtilis aprE 5 '-untranslated region sequence (mod-5'-UTR) of SEQ ID NO: 63, wherein the mod-5'-UTR is downstream (3') and operably linked to the promoter sequence and upstream (5') and operably linked to the ORF sequence. In another embodiment, the DNA construct further comprises a terminator sequence downstream (3') and operably linked to the ORF sequence.

[0116] Other embodiments of the disclosure are related to compositions and methods for producing increased amounts of an endogenous protein of interest (POI) and/or a heterologous POI in a modified Bacillus (host) cell of the disclosure. For example, in certain embodiments, a method for producing increased amounts of an endogenous protein of interest (POI) in a modified Bacillus (host) cell of the disclosure comprises (a) cultivating a modified Bacillus (host) cell comprising a glcT gene encoding a GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55, in a medium suitable for the production of an endogenous POI and (b) recovering the endogenous POI from the cultivation medium, wherein the modified Bacillus cell produces an increased amount of the endogenous POI relative to an unmodified (parental) Bacillus cell producing the same endogenous POI, when cultivated under identical conditions.

[0117] In certain other embodiments, the disclosure is related to a method for producing increased amounts of a heterologous POI in a modified Bacillus (host) cell of the disclosure comprising (a) cultivating a modified Bacillus (host) cell comprising a modified glcT gene encoding a variant GlcT protein (i.e.. comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55) in a medium suitable for the production of a heterologous POI, wherein the modified cell and parental cell comprise an introduced polynucleotide sequence directing synthesis of the heterologous POI and (b) recovering the heterologous POI from the cultivation medium, wherein the modified Bacillus cell produces an increased amount of the heterologous POI relative to the parental Bacillus cell (i.e., comprising a wild-type glcT gene encoding a wild-type GlcT protein of SEQ ID NO: 82), when cultivated under identical conditions.

[0118] Thus, certain other embodiments of the disclosure are related to compositions and methods for constructing such modified Bacillus cells capable of producing increased amounts heterologous and/or endogenous proteins of interest. For example, certain compositions and methods are related to modified Bacillus (daughter) cells derived from unmodified Bacillus (parental) cells comprising (a) obtaining a parental Bacillus cell comprising an endogenous chromosomal wild-type glcT gene encoding a GlcT protein comprising at least 90% sequence identity to SEQ ID NO: 82 and comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82, (b) modifying the parental cell of step (a) by introducing a polynucleotide sequence directing synthesis of a variant GlcT protein comprising 90% sequence identity to SEQ ID NO: 55, comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55, and (c) cultivating the modified B. licheniformis (daughter) cell in a medium suitable for the production of the POI, wherein the modified B. licheniformis (daughter) cell produces an increased amount of the POI relative to the parental B. licheniformis cell producing the same POI, when daughter and parental cells are cultivated under identical conditions. Thus, in certain other embodiments, a modified Bacillus (daughter) cell of the disclosure is derived from an unmodified Bacillus (parental) cell, wherein the endogenous chromosomal wild-type glcT gene (i.e., comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 82) in the parental cell is modified by means of a Cas9 targeting vector, wherein the edited (modified) glcT gene encodes a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. Thus, certain embodiments of the disclosure are related to Cas9 edited genes, including, but not limited to, a Cas9 edited glcT gene, a Cas9 edited rghr2 gene, combinations thereof and the like.

[0119] In certain embodiments, the POI is a heterologous POI, wherein a polynucleotide sequence directing synthesis of the heterologous POI is introduced into the daughter and parental cells. In other embodiments, the POI is an endogenous or heterologous enzyme.

I. DEFINITIONS

[0120] In view of the modified Bacillus sp. cells producing one or more heterologous and/or endogenous proteins of interest, and methods thereof described herein, the following terms and phrases are defined. Terms not defined herein should be accorded their ordinary meaning as used in the art.

[0121] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present compositions and methods apply. Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present compositions and methods, representative illustrative methods and materials are now described. All publications and patents cited herein are incorporated by reference in their entirety.

[0122] It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as“solely,”“only”, “excluding”,“not including” and the like, in connection with the recitation of claim elements, or use of a “negative” limitation or proviso thereof.

[0123] As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present compositions and methods described herein. Any recited method can be carried out in the order of events recited or in any other order which is logically possible.

[0124] As used herein,“host cell” refers to a cell that has the capacity to act as a host or expression vehicle for a newly introduced DNA sequence. Thus, in certain embodiments of the disclosure, the host cells are Bacillus sp. cells or A. coli cells.

[0125] As defined herein, a“parental cell” or a“parental (host) cell” may be used interchangeably and refer to “unmodified” parental cells. For example, a“parental” cell refers to any cell or strain of microorganism in which the genome of the “parental” cell is altered ( e.g ., via one or more mutations/modifications introduced into the parental cell) to generate a modified“daughter” cell thereof.

[0126] As used herein, a“modified cell” or a“modified (host) cell” may be used interchangeably and refer to recombinant (host) cells that comprise at least one genetic modification which is not present in the “parental” host cell from which the modified cells are derived.

[0127] In certain embodiments, the“unmodified” (parental) cell may be referred to as a“control cell”, particularly when being compared with, or relative to, a“modified” Bacillus sp. (daughter) cell. As used herein, when the expression and/or production of a protein of interest (POI) in an“unmodified” (parental) cell (e.g., a control cell) is being compared to the expression and/or production of the same POI in a “modified” (daughter) cell, it will be understood that the “modified” and “unmodified” cells are grown/cultivated/fermented under the same conditions (e.g., the same conditions such as media, temperature, pH and the like).

[0128] As used herein,“the genus Bacillus’’ or“ Bacillus sp” cells include all species within the genus “ Bacillus ^’ ’” as known to those of skill in the art, including but not limited to B. subtilis, B. licheniformis, B. lentus, B. brevis, B. stearothermophilus, B. alkalophilus, B. amyloliquefaciens, B. clausii, B. halodurans, B. megaterium, B. coagulans, B. circulans, B. lautus, and B. thuringiensis . It is recognized that the genus Bacillus continues to undergo taxonomical reorganization. Thus, it is intended that the genus include species that have been reclassified, including but not limited to such organisms as B. stearothermophilus , which is now named“ Geobacillus stearothermophilus” .

[0129] As used herein, a polynucleotide sequence of SEQ ID NO: 22 encodes a wild-type GlcT protein of SEQ ID NO: 82, and a polynucleotide sequence of SEQ ID NO: 56 encodes a variant GlcT protein of SEQ ID NO: 55. For example, as presented in FIG. 1A of the disclosure, the two aligned polynucleotide (ORF) sequences (SEQ ID NO: 22 vs. SEQ ID NO: 56), differ by a SNP at nucleotide position 199, wherein position 199 of SEQ ID NO: 22 comprises a cytosine (C) and position 199 of SEQ ID NO: 56 comprises a thymine (T) (e.g., see FIG. 1A black boxed nucleotides (C) and (T) at position 199). Similarly, FIG. 1B presents an alignment of the encoded wild-type GlcT protein (SEQ ID NO: 82) and the encoded variant GlcT protein (SEQ ID NO: 55), wherein the (C) to (T) SNP at position 199 of SEQ ID NO: 56 (see, FIG. 1A), results in a leucine (L) to phenylalanine (F) substitution at amino acid residue position 67 of SEQ ID NO: 55 (e.g., see FIG. 1B, black boxed (L) and (F) amino acids at residue position 67 of SEQ ID NO: 22 and SEQ ID NO: 55, respectively).

[0130] As used herein, the term“ glcTl” or“allele glcTl” particularly refers to a Bacillus sp. cell comprising a mutated, modified, edited or introduced glcT gene (i.e., allele glcTl·, SEQ ID NO: 56) encoding the L67F GlcT protein of SEQ ID NO: 55. In certain embodiments, allele glcTl encodes a GlcT protein having about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 55 and comprises a L67F substation at amino acid position 67 of SEQ ID NO: 55.

[0131] As used herein, a“wild-type B. subtilis aprE 5'-UTR” (abbreviated hereinafter,“WT-5'-UTR”) comprises SEQ ID NO: 62 and a“modified aprE 5'-UTR” (abbreviated hereinafter,“mod-5'-UTR”) comprises SEQ ID NO: 63. For example, the a-amylase expression cassettes described in Example 7 (i.e., SEQ ID NO: 64 and SEQ ID NO: 65) were constructed to additionally test the effect of an operably linked “WT-5'-UTR sequence” versus an operably linked“mod-5 '-UTR sequence” on the expression/production of the heterologous a-amylase. Thus, the a-amylase expression cassettes comprised either a WT-5'-UTR sequence (SEQ ID NO: 62) or a mod-5'-UTR sequence (SEQ ID NO: 63) operably linked to an upstream (5') promoter and a downstream (3') open reading frame encoding the a-amylase.

[0132] As used herein, a“ Bacillus (daughter) cell/strain” named“BF134” comprises an introduced amylase expression construct of SEQ ID NO: 64.

[0133] As used herein, a“ Bacillus (daughter) cell/strain” named“BF117” comprises an introduced amylase expression construct of SEQ ID NO: 65.

[0134] As used herein, a “ Bacillus (daughter) cell/strain” named “BF63” comprises allele glcTl (g/c77(L67F) / pBL.comK) encoding the L67F GlcT protein of SEQ ID NO: 55 and plasmid pBL.comK encoding/expressing a ComK protein. [0135] As used herein, a“ Bacillus (daughter) cell/strain” named“HM151” comprises allele glcTl and an introduced amylase expression construct of SEQ ID NO: 64.

[0136] As used herein, a“ Bacillus (daughter) cell/strain” named“HM150-1” comprises allele glcTl and an introduced amylase expression construct of SEQ ID NO: 65.

[0137] As used herein, a“ Bacillus (daughter) cell/strain” named“BF62” comprises a restored rghr2 gene (hereinafter, rghr2 _K f). The rghr2 gene and its restored form“ rghr2 _{KS t} ” are further described below.

[0138] As used herein, a“ Bacillus (daughter) cell/strain” named“BF165” comprises rghr2 _KSi and an introduced amylase expression construct of SEQ ID NO: 64.

[0139] As used herein, a“ Bacillus (daughter) cell/strain” named“BF118” comprises rghr2 _KSi and an introduced amylase expression construct of SEQ ID NO: 65.

[0140] As used herein, a“ Bacillus (daughter) cell/strain” named“BF260” comprises allele glcTl and rghr2 _ms{ , and an introduced amylase expression construct of SEQ ID NO: 64.

[0141] As used herein, a“ Bacillus (daughter) cell/strain” named“BF171” comprises allele glcTl and rghr2 _ms{ , and an introduced amylase expression construct of SEQ ID NO: 65.

[0142] As used herein, a“variant B. licheniformis chromosomal rghR2 gene” of SEQ ID NO: 41 comprises an 18-nucleotide (l8-bp) duplication encoding a consecutive repeat of six (6) amino acids which are“Ala-Ala-Ala-Ile-Ser-Arg” (hereinafter“AAAISR”), wherein the primary (1°) amino acid sequence of the encoded variant RghR2 protein of SEQ ID NO: 83 comprises a linear (consecutive) repeat of these six (6) amino acids as follows: “Ala-Ala-Ala-Ile-Ser-Arg-Ala-Ala-Ala-Ile-Ser-Arg”; hereinafter, “AAAISRAAAISR”. For example, the six amino acid repeat present in RghR2 protein of SEQ ID NO: 83 is set forth below in Table 1, wherein the repeated amino acid residues of this 140 amino acid protein comprise the bold text amino acids at positions 38-43 of SEQ ID NO: 83.

[0143] In contrast, a“restored B. licheniformis chromosomal rghR2 gene” of the disclosure (SEQ ID NO: 61) does not comprise this l8-nucleotide (l8-bp) duplication. Thus, the restored rghR2 gene of SEQ ID NO: 61 encodes a native RghR2 protein of SEQ ID NO: 84 (i.e.. which does not comprise the consecutive repeat“AAAISR”).

TABLE 1

VARIANT AND RESTORED (NATIVE) RghR2 PROTEINS

[0144] Thus, as used herein, the phrases“deleting the 18-nucleotide duplication”, or“deleting the l8-bp duplication” or“modifying the cell by deleting the 18-nucleotide duplication” particularly refer to a genetic modification of a parental Bacillus cell comprising a variant rghR2 gene comprising an 18-nucleotide duplication, which duplication encodes a repeat of amino acids“AAAISR” in the variant RghR2 protein (e.g., see Table 1; SEQ ID NO: 83, wherein amino acids“AAAISR” at positions 32-37 of SEQ ID NO: 83 are consecutively repeated at positions 38-43 of SEQ ID NO: 83). Thus, in certain embodiments, a modified Bacillus cell of the disclosure is derived from a parental Bacillus cell comprising a variant chromosomal rghR2 gene comprising an 18-nucleotide duplication encoding the“AAAISR” repeated sequence, wherein the modified Bacillus cell is modified by“deleting the 18-nucleotide duplication”, thereby resulting in a modified Bacillus cell comprising a“restored” rghR2 gene ( rghR2 _KSt ) sequence encoding a native rghR2 protein of SEQ ID NO: 84. For a more detailed description of the rghR2 gene, the (l8-bp duplication) rghR2 variant thereof (SEQ ID NO: 83) and the restoration of the rghR2 variant back to a native rghR2 gene ( rghR2 _KSi ; SEQ ID NO: 84), see Applicant’s U.S. Provisional Patent Application Serial No. 62/463,268, filed February 24, 2017, incorporated herein by reference in its entirety.

[0145] As defined herein, the terms“increased expression”,“enhanced expression”,“increased expression of a POI”,“increased production”,“increased production of a POI” and the like refer to a“modified” Bacillus (daughter) cell, wherein the“increase” is always relative (vis-a-vis) to an“unmodified” Bacillus (parental) cell expressing/producing the same POI.

[0146] As used herein, the term“expression” refers to the transcription and stable accumulation of sense (mRNA) or anti-sense RNA, derived from a nucleic acid molecule of the disclosure. Expression may also refer to translation of mRNA into a polypeptide. Thus, the term“expression” includes any step involved in the production of the polypeptide including, but not limited to, transcription, post-transcriptional modification, translation, post-translational modification, secretion and the like.

[0147] As defined herein, the combined term“expresses/produces”, as used in phrases such as“a modified host cell expresses/produces an increased amount of a protein of interest relative to the (unmodified) parental host cell”, the term (“expresses/produces”) is meant to include any steps involved in the expression and production of a protein of interest in host cell of the disclosure.

[0148] Likewise, as used herein, an“increased amount”, when used in phrases such as“a modified host cell ‘expresses/produces an increased amount’ of one or more proteins of interest relative to the (unmodified) parental host cell”, particularly refers to an“increased amount” of any protein of interest (POI) expressed/produced in the modified host cell, which“increased amount” is always relative to the (unmodified) parental Bacillus cells expressing/producing the same POI, wherein the modified and unmodified cells are grown/cultured/fermented under essentially the same conditions (e.g., the same conditions such as media, temperature, pH and the like). For example, an increased amount of a POI may be an endogenous Bacillus POI or a heterologous POI expressed in a modified Bacillus cell of the disclosure.

[0149] Thus, as used herein,“increasing” protein production or“increased” protein production is meant an increased amount of protein produced (e.g., a protein of interest). The protein may be produced inside the host cell, or secreted (or transported) into the culture medium. In certain embodiments, the protein of interest is produced (secreted) into the culture medium. Increased protein production may be detected for example, as higher maximal level of protein or enzymatic activity (e.g., such as protease activity, amylase activity, cellulase activity, hemicellulase activity and the like), or total extracellular protein produced as compared to the parental host cell.

[0150] As used herein,“nucleic acid” refers to a nucleotide or polynucleotide sequence, and fragments or portions thereof, as well as to DNA, cDNA, and RNA of genomic or synthetic origin, which may be double -stranded or single-stranded, whether representing the sense or antisense strand. It will be understood that as a result of the degeneracy of the genetic code, a multitude of nucleotide sequences may encode a given protein.

[0151] It is understood that the polynucleotides (or nucleic acid molecules) described herein include “genes”,“vectors” and“plasmids”.

[0152] Accordingly, the term“gene”, refers to a polynucleotide that codes for a particular sequence of amino acids, which comprise all, or part of a protein coding sequence, and may include regulatory (non- transcribed) DNA sequences, such as promoter sequences, which determine for example the conditions under which the gene is expressed. The transcribed region of the gene may include untranslated regions (UTRs), including introns, 5 '-untranslated regions (UTRs), and 3'-UTRs, as well as the coding sequence.

[0153] As used herein, the term“coding sequence” refers to a nucleotide sequence, which directly specifies the amino acid sequence of its (encoded) protein product. The boundaries of the coding sequence are generally determined by an open reading frame (hereinafter,“ORF”), which usually begins with an ATG start codon. The coding sequence typically includes DNA, cDNA, and recombinant nucleotide sequences. [0154] As defined herein, the term“open reading frame” (hereinafter,“ORF”) means a nucleic acid or nucleic acid sequence (whether naturally occurring, non-naturally occurring, or synthetic) comprising an uninterrupted reading frame consisting of (i) an initiation codon, (ii) a series of two (2) or more codons representing amino acids, and (iii) a termination codon, the ORF being read (or translated) in the 5' to 3' direction.

[0155] The term“promoter” as used herein refers to a nucleic acid sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' (downstream) to a promoter sequence. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic nucleic acid segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different cell types, or at different stages of development, or in response to different environmental or physiological conditions. Promoters which cause a gene to be expressed in most cell types at most times are commonly referred to as“constitutive promoters”. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, DNA fragments of different lengths may have identical promoter activity.

[0156] The term“operably linked” as used herein refers to the association of nucleic acid sequences on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence (e.g., an ORF) when it is capable of affecting the expression of that coding sequence (i.e.. that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

[0157] A nucleic acid is“operably linked” when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA encoding a secretory leader (i.e., a signal peptide), is operably linked to DNA for a polypeptide if it is expressed as a pre-protein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally,“operably linked” means that the DNA sequences being linked are contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.

[0158] As used herein,“a functional promoter sequence controlling the expression of a gene of interest (or open reading frame thereof) linked to the gene of interest’s protein coding sequence” refers to a promoter sequence which controls the transcription and translation of the coding sequence in Bacillus. For example, in certain embodiments, the present disclosure is directed to a polynucleotide comprising a 5' promoter (or 5' promoter region, or tandem 5' promoters and the like), wherein the promoter region is operably linked to a nucleic acid sequence encoding a protein of interest. Thus, in certain embodiments, a functional promoter sequence controls the expression of a gene of interest encoding a protein of interest. In other embodiments, a functional promoter sequence controls the expression of a heterologous gene or an endogenous gene encoding a protein of interest in a Bacillus cell.

[0159] As defined herein,“suitable regulatory sequences” refer to nucleotide sequences located upstream (5 ¹ non-coding sequences), within, or downstream (3 ¹ non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, RNA processing site, effector binding site and stem -loop structure.

[0160] As defined herein, the term“introducing”, as used in phrases such as“introducing into a bacterial cell” or“introducing into a Bacillus cell” at least one polynucleotide open reading frame (ORF), or a gene thereof, or a vector thereof, includes methods known in the art for introducing polynucleotides into a cell, including, but not limited to protoplast fusion, natural or artificial transformation (e.g., calcium chloride, electroporation), transduction, transfection, conjugation and the like (e.g., see Ferrari et al., 1989).

[0161] As used herein,“transformed” or“transformation” mean a cell has been transformed by use of recombinant DNA techniques. Transformation typically occurs by insertion of one or more nucleotide sequences (e.g., a polynucleotide, an ORF or gene) into a cell. The inserted nucleotide sequence may be a heterologous nucleotide sequence (i.e., a sequence that is not naturally occurring in cell that is to be transformed). As used herein,“transformation” refers to introducing an exogenous DNA into a host cell so that the DNA is maintained as a chromosomal integrant or a self-replicating extra-chromosomal vector. As used herein,“transforming DNA”,“transforming sequence”, and“DNA construct” refer to DNA that is used to introduce sequences into a host cell or organism. Transforming DNA is DNA used to introduce sequences into a host cell or organism. The DNA may be generated in vitro by PCR or any other suitable techniques. In some embodiments, the transforming DNA comprises an incoming sequence, while in other embodiments it further comprises an incoming sequence flanked by homology boxes. In yet a further embodiment, the transforming DNA comprises other non-homologous sequences, added to the ends (i.e., staffer sequences or flanks). The ends can be closed such that the transforming DNA forms a closed circle, such as, for example, insertion into a vector.

[0162] As used herein“an incoming sequence” refers to a DNA sequence that is introduced into the Bacillus chromosome. In some embodiments, the incoming sequence is part of a DNA construct. In other embodiments, the incoming sequence encodes one or more proteins of interest. In some embodiments, the incoming sequence comprises a sequence that may or may not already be present in the genome of the cell to be transformed (i.e., it may be either a homologous or heterologous sequence). In some embodiments, the incoming sequence encodes one or more proteins of interest, a gene, and/or a mutated or modified gene. In alternative embodiments, the incoming sequence encodes a functional wild-type gene or operon, a functional mutant gene or operon, or a nonfunctional gene or operon. In some embodiments, the non functional sequence may be inserted into a gene to disrupt function of the gene. In another embodiment, the incoming sequence includes a selective marker. In a further embodiment the incoming sequence includes two homology boxes (e.g., up-stream and down-stream homology arms).

[0163] As used herein,“homology box” refers to a nucleic acid sequence, which is homologous to a sequence in the Bacillus chromosome. More specifically, a homology box is an upstream or downstream region having between about 80 and 100% sequence identity, between about 90 and 100% sequence identity, or between about 95 and 100% sequence identity with the immediate flanking coding region of a gene or part of a gene to be deleted, disrupted, inactivated, down-regulated and the like, according to the invention. These sequences direct where in the Bacillus chromosome a DNA construct is integrated and directs what part of the Bacillus chromosome is replaced by the incoming sequence. While not meant to limit the present disclosure, a homology box may include about between 1 base pair (bp) to 200 kilobases (kb). Preferably, a homology box includes about between 1 bp and 10.0 kb; between 1 bp and 5.0 kb; between 1 bp and 2.5 kb; between 1 bp and 1.0 kb, and between 0.25 kb and 2.5 kb. A homology box may also include about 10.0 kb, 5.0 kb, 2.5 kb, 2.0 kb, 1.5 kb, 1.0 kb, 0.5 kb, 0.25 kb and 0.1 kb. In some embodiments, the 5 'and 3' ends of a selective marker are flanked by a homology box (homology arms) wherein the homology box comprises nucleic acid sequences immediately flanking the coding region of the gene.

[0164] In still another embodiment of the disclosure, the deletion, disruption, inactivation or down- regulation of a gene active at an inappropriate time, as determined by DNA array analysis (e.g., transcriptome analysis, as described herein) provides enhanced expression of a protein of interest. As used herein,“transcriptome analysis” refers to the analysis of gene transcription.

[0165] As used herein, the term“selectable marker-encoding nucleotide sequence” refers to a nucleotide sequence which is capable of expression in the host cells and where expression of the selectable marker confers to cells containing the expressed gene the ability to grow in the presence of a corresponding selective agent or lack of an essential nutrient.

[0166] As used herein, the terms“selectable marker” and“selective marker” refer to a nucleic acid (e.g., a gene) capable of expression in host cell which allows for ease of selection of those hosts containing the vector. Examples of such selectable markers include, but are not limited to, antimicrobials. Thus, the term “selectable marker” refers to genes that provide an indication that a host cell has taken up an incoming DNA of interest or some other reaction has occurred. Typically, selectable markers are genes that confer antimicrobial resistance or a metabolic advantage on the host cell to allow cells containing the exogenous DNA to be distinguished from cells that have not received any exogenous sequence during the transformation.

[0167] A“residing selectable marker” is one that is located on the chromosome of the microorganism to be transformed. A residing selectable marker encodes a gene that is different from the selectable marker on the transforming DNA construct. Selective markers are well known to those of skill in the art. As indicated above, the marker can be an antimicrobial resistance marker (e.g., amp ^R , phleo ^R , spec ^R , kan ^R , ery ^R , tet ^R , cmp ^R and neo ^R (see e.g., Guerot-Fleury, 1995; Palmeros el al, 2000; and Trieu-Cuot etal, 1983). In some embodiments, the present invention provides a chloramphenicol resistance gene (e.g., the gene present on pCl94, as well as the resistance gene present in the Bacillus licheniformis genome). This resistance gene is particularly useful in the present invention, as well as in embodiments involving chromosomal amplification of chromosomally integrated cassettes and integrative plasmids (See e.g., Albertini and Galizzi, 1985; Stahl and Ferrari, 1984). Other markers useful in accordance with the invention include, but are not limited to auxotrophic markers, such as serine, lysine, tryptophan; and detection markers, such as b-galactosidase.

[0168] As defined herein, a host cell“genome”, a bacterial (host) cell“genome”, or a Bacillus (host) cell “genome” includes chromosomal and extrachromosomal genes.

[0169] As used herein, the terms“plasmid”,“vector” and“cassette” refer to extrachromosomal elements, often carrying genes which are typically not part of the central metabolism of the cell, and usually in the form of circular double-stranded DNA molecules. Such elements may be autonomously replicating sequences, genome integrating sequences, phage or nucleotide sequences, linear or circular, of a single- stranded or double-stranded DNA or RNA, derived from any source, in which a number of nucleotide sequences have been joined or recombined into a unique construction which is capable of introducing a promoter fragment and DNA sequence for a selected gene product along with appropriate 3' untranslated sequence into a cell.

[0170] A used herein, a“transformation cassette” refers to a specific vector comprising a gene (or ORF thereof), and having elements in addition to the foreign gene that facilitate transformation of a particular host cell.

[0171] As used herein, the term“vector” refers to any nucleic acid that can be replicated (propagated) in cells and can carry new genes or DNA segments into cells. Thus, the term refers to a nucleic acid construct designed for transfer between different host cells. Vectors include viruses, bacteriophage, pro-viruses, plasmids, phagemids, transposons, and artificial chromosomes such as YACs (yeast artificial chromosomes), BACs (bacterial artificial chromosomes), PLACs (plant artificial chromosomes), and the like, that are“episomes” (i.e.. replicate autonomously or can integrate into a chromosome of a host organism). [0172] An“expression vector” refers to a vector that has the ability to incorporate and express heterologous DNA in a cell. Many prokaryotic and eukaryotic expression vectors are commercially available and know to one skilled in the art. Selection of appropriate expression vectors is within the knowledge of one skilled in the art.

[0173] As used herein, the terms“expression cassette” and“expression vector” refer to a nucleic acid construct generated recombinantly or synthetically, with a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell (i.e., these are vectors or vector elements, as described above). The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of an expression vector includes, among other sequences, a nucleic acid sequence to be transcribed and a promoter. In some embodiments, DNA constructs also include a series of specified nucleic acid elements that permit transcription of a particular nucleic acid in a target cell. In certain embodiments, a DNA construct of the disclosure comprises a selective marker and an inactivating chromosomal or gene or DNA segment as defined herein.

[0174] As used herein, a“targeting vector” is a vector that includes polynucleotide sequences that are homologous to a region in the chromosome of a host cell into which the targeting vector is transformed and that can drive homologous recombination at that region. For example, targeting vectors find use in introducing mutations into the chromosome of a host cell through homologous recombination. In some embodiments, the targeting vector comprises other non-homologous sequences, e.g., added to the ends (i.e.. staffer sequences or flanking sequences). The ends can be closed such that the targeting vector forms a closed circle, such as, for example, insertion into a vector. Selection and/or construction of appropriate vectors is well within the knowledge of those having skill in the art.

[0175] As used herein, the term“plasmid” refers to a circular double-stranded (ds) DNA construct used as a cloning vector, and which forms an extrachromosomal self-replicating genetic element in many bacteria and some eukaryotes. In some embodiments, plasmids become incorporated into the genome of the host cell.

[0176] As used herein, the term“protein of interest” or“POI” refers to a polypeptide of interest that is desired to be expressed in a modified Bacillus (daughter) cell, wherein the POI is preferably expressed at increased levels (i.e.. relative to the“unmodified” (parental) cell). Thus, as used herein, a POI may be an enzyme, a substrate-binding protein, a surface-active protein, a structural protein, a receptor protein, an antibody and the like

[0177] Similarly, as defined herein, a“gene of interest” or“GOI” refers a nucleic acid sequence (e.g., a polynucleotide, a gene or an ORF) which encodes a POI. A“gene of interest” encoding a“protein of interest” may be a naturally occurring gene, a mutated gene or a synthetic gene. [0178] In certain embodiments, a modified cell of the disclosure produces an increased amount of a heterologous POI or an endogenous POI relative to the parental cell. In particular embodiments, an increased amount of a POI produced by a modified cell of the disclosure is at least a 0.05% increase, at least 0.10%, at least a 1.0% increase, at least a 5.0% increase, or a greater than 5.0% increase, relative to the parental cell. As a non-limiting example, in certain embodiments, the POI is an enzyme (e.g., amylase, a protease, etc.), wherein an increased level of the POI produced by the modified cell (i.e., relative to its unmodified parent) is detected or measured as an increase in enzymatic activity and/or an increase specific productivity (Qp).

[0179] As used herein, the terms“polypeptide” and“protein” are used interchangeably, and refer to polymers of any length comprising amino acid residues linked by peptide bonds. The conventional one (1) letter or three (3) letter codes for amino acid residues are used herein. The polypeptide may be linear or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids. The term polypeptide also encompasses an amino acid polymer that has been modified naturally or by intervention; for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling component. Also included within the definition are, for example, polypeptides containing one or more analogs of an amino acid (including, for example, unnatural amino acids, etc.), as well as other modifications known in the art.

[0180] In certain embodiments, a gene of the instant disclosure encodes a commercially relevant industrial protein of interest, such as an enzyme (e.g., a acetyl esterases, aminopeptidases, amylases, arabinases, arabinofuranosidases, carbonic anhydrases, carboxypeptidases, catalases, cellulases, chitinases, chymosins, cutinases, deoxyribonucleases, epimerases, esterases, a-galactosidases, b-galactosidases, a-glucanases, glucan lysases, endo^-glucanases, glucoamylases, glucose oxidases, a- glucosidases, b-glucosidases, glucuronidases, glycosyl hydrolases, hemicellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, lipases, lyases, mannosidases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectin depolymerases, pectin methyl esterases, pectinolytic enzymes, perhydrolases, polyol oxidases, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, peptidases, rhamno-galacturonases, ribonucleases, transferases, transport proteins, transglutaminases, xylanases, hexose oxidases, and combinations thereof).

[0181] As used herein, a“variant” polypeptide refers to a polypeptide that is derived from a parent (or reference) polypeptide by the substitution, addition, or deletion of one or more amino acids, typically by recombinant DNA techniques. Variant polypeptides may differ from a parent polypeptide by a small number of amino acid residues and may be defined by their level of primary amino acid sequence homology/identity with a parent (reference) polypeptide. [0182] Preferably, variant polypeptides have at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or even at least 99% amino acid sequence identity with a parent (reference) polypeptide sequence. As used herein, a“variant” polynucleotide refers to a polynucleotide encoding a variant polypeptide, wherein the “variant polynucleotide” has a specified degree of sequence homology/identity with a parent polynucleotide, or hybridizes with a parent polynucleotide (or a complement thereof) under stringent hybridization conditions. Preferably, a variant polynucleotide has at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or even at least 99% nucleotide sequence identity with a parent (reference) polynucleotide sequence.

[0183] As used herein, a“mutation” refers to any change or alteration in a nucleic acid sequence. Several types of mutations exist, including point mutations, deletion mutations, silent mutations, frame shift mutations, splicing mutations and the like. Mutations may be performed specifically (e.g., via site directed mutagenesis) or randomly (e.g., via chemical agents, passage through repair minus bacterial strains).

[0184] As used herein, in the context of a polypeptide or a sequence thereof, the term“substitution” means the replacement (i.e., substitution) of one amino acid with another amino acid.

[0185] As defined herein, an“endogenous gene” refers to a gene in its natural location in the genome of an organism.

[0186] As defined herein, a“heterologous” gene, a“non-endogenous” gene, or a“foreign” gene refer to a gene (or ORF) not normally found in the host organism, but that is introduced into the host organism by gene transfer. As used herein, the term“foreign” gene(s) comprise native genes (or ORFs) inserted into a non-native organism and/or chimeric genes inserted into a native or non-native organism.

[0187] As defined herein, a“heterologous” nucleic acid construct or a“heterologous” nucleic acid sequence has a portion of the sequence which is not native to the cell in which it is expressed.

[0188] As defined herein, a“heterologous control sequence”, refers to a gene expression control sequence (e.g., a promoter or enhancer) which does not function in nature to regulate (control) the expression of the gene of interest. Generally, heterologous nucleic acid sequences are not endogenous (native) to the cell, or a part of the genome in which they are present, and have been added to the cell, by infection, transfection, transformation, microinjection, electroporation, and the like. A“heterologous” nucleic acid construct may contain a control sequence/DNA coding (ORF) sequence combination that is the same as, or different, from a control sequence/DNA coding sequence combination found in the native host cell.

[0189] As used herein, the terms“signal sequence” and“signal peptide” refer to a sequence of amino acid residues that may participate in the secretion or direct transport of a mature protein or precursor form of a protein. The signal sequence is typically located N-terminal to the precursor or mature protein sequence. The signal sequence may be endogenous or exogenous. A signal sequence is normally absent from the mature protein. A signal sequence is typically cleaved from the protein by a signal peptidase after the protein is transported.

[0190] The term“derived” encompasses the terms“originated”“obtained,”“obtainable,” and“created,” and generally indicates that one specified material or composition finds its origin in another specified material or composition, or has features that can be described with reference to the another specified material or composition.

[0191] As used herein, the term“homology” relates to homologous polynucleotides or polypeptides. If two or more polynucleotides or two or more polypeptides are homologous, this means that the homologous polynucleotides or polypeptides have a“degree of identity” of at least 60%, more preferably at least 70%, even more preferably at least 85%, still more preferably at least 90%, more preferably at least 95%, and most preferably at least 98%. Whether two polynucleotide or polypeptide sequences have a sufficiently high degree of identity to be homologous as defined herein, can suitably be investigated by aligning the two sequences using a computer program known in the art, such as“GAP” provided in the GCG program package (Program Manual for the Wisconsin Package, Version 8, August 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711) (Needleman and Wunsch, (1970). Using GAP with the following settings for DNA sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3.

[0192] As used herein, the term“percent (%) identity” refers to the level of nucleic acid or amino acid sequence identity between the nucleic acid sequences that encode a polypeptide or the polypeptide's amino acid sequences, when aligned using a sequence alignment program.

[0193] As used herein,“specific productivity” is total amount of protein produced per cell per time over a given time period.

[0194] As defined herein, the terms“purified”,“isolated” or“enriched” are meant that a biomolecule (e.g., a polypeptide or polynucleotide) is altered from its natural state by virtue of separating it from some, or all of, the naturally occurring constituents with which it is associated in nature. Such isolation or purification may be accomplished by art-recognized separation techniques such as ion exchange chromatography, affinity chromatography, hydrophobic separation, dialysis, protease treatment, ammonium sulphate precipitation or other protein salt precipitation, centrifugation, size exclusion chromatography, filtration, microfiltration, gel electrophoresis or separation on a gradient to remove whole cells, cell debris, impurities, extraneous proteins, or enzymes undesired in the final composition. It is further possible to then add constituents to a purified or isolated biomolecule composition which provide additional benefits, for example, activating agents, anti-inhibition agents, desirable ions, compounds to control pH or other enzymes or chemicals. [0195] As used herein, a “variant Geobacillus stearothermophilus amylase” is a variant G. stearothermophilus a-amylase disclosed in International PCT Publication No. W02009/149130.

[0196] As used herein, the term“ComK polypeptide” is defined as the product of a comK gene; a transcription factor that acts as the final auto-regulatory control switch prior to competence development; involved with activation of the expression of late competence genes involved in DNA-binding and uptake and in recombination (Liu and Zuber, 1998, Hamoen et al., 1998). A plasmid (pBL.comK) comprising and expressing the comK nucleic acid sequence is set forth in SEQ ID NO: 50.

[0197] As used herein,“homologous genes” refers to a pair of genes from different, but usually related species, which correspond to each other and which are identical or very similar to each other. The term encompasses genes that are separated by speciation (i.e., the development of new species) (e.g., orthologous genes), as well as genes that have been separated by genetic duplication (e.g., paralogous genes).

[0198] As used herein,“orthologue” and“orthologous genes” refer to genes in different species that have evolved from a common ancestral gene (i.e., a homologous gene) by speciation. Typically, orthologs retain the same function during the course of evolution. Identification of orthologs finds use in the reliable prediction of gene function in newly sequenced genomes.

[0199] As used herein,“paralog” and“paralogous genes” refer to genes that are related by duplication within a genome. While orthologs retain the same function through the course of evolution, paralogs evolve new functions, even though some functions are often related to the original one. Examples of paralogous genes include, but are not limited to genes encoding trypsin, chymotrypsin, elastase, and thrombin, which are all serine proteinases and occur together within the same species.

[0200] As used herein,“homology” refers to sequence similarity or identity, with identity being preferred. This homology is determined using standard techniques known in the art (See e.g., Smith and Waterman, 1981; Needleman and Wunsch, 1970; Pearson and Lipman, 1988; programs such as GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package (Genetics Computer Group, Madison, WI) and Devereux et. al, 1984).

[0201] As used herein, an“analogous sequence” is one wherein the function of the gene is essentially the same as the gene derived from a Bacillus cell. Additionally, analogous genes include at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% sequence identity with the sequence of the Bacillus sp. cell. Analogous sequences are determined by known methods of sequence alignment. A commonly used alignment method is BLAST, although there are other methods that also find use in aligning sequences.

[0202] As used herein, the term“hybridization” refers to the process by which a strand of nucleic acid joins with a complementary strand through base pairing, as known in the art. A nucleic acid sequence is considered to be“selectively hybridizable” to a reference nucleic acid sequence if the two sequences specifically hybridize to one another under moderate to high stringency hybridization and wash conditions. Hybridization conditions are based on the melting temperature (T _m ) of the nucleic acid binding complex or probe. For example,“maximum stringency” typically occurs at about T _m ^~ 5°C (5°below the T _m of the probe);“high stringency” at about 5-l0°C below the T _m ;“intermediate stringency” at about l0-20°C below the T _m of the probe; and“low stringency” at about 20-25°C below the T _m . Functionally, maximum stringency conditions may be used to identify sequences having strict identity or near-strict identity with the hybridization probe; while an intermediate or low stringency hybridization can be used to identify or detect polynucleotide sequence homologs. Moderate and high stringency hybridization conditions are well known in the art. An example of high stringency conditions includes hybridization at about 42°C in 50% formamide, 5X SSC, 5X Denhardfs solution, 0.5% SDS and 100 pg/ml denatured carrier DNA, followed by washing two times in 2X SSC and 0.5% SDS at room temperature (RT) and two additional times in 0. IX SSC and 0.5% SDS at 42°C. An example of moderate stringent conditions including overnight incubation at 37°C in a solution comprising 20% formamide, 5 x SSC (l50mM NaCI, 15 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5 x Denhardt's solution, 10% dextran sulfate and 20 mg/ml denaturated sheared salmon sperm DNA, followed by washing the filters in lx SSC at about 37-50°C. Those of skill in the art know how to adjust the temperature, ionic strength, etc. as necessary to accommodate factors such as probe length and the like.

[0203] As used herein,“recombinant" includes reference to a cell or vector, that has been modified by the introduction of a heterologous nucleic acid sequence or that the cell is derived from a cell so modified. Thus, for example, recombinant cells express genes that are not found in identical form within the native (non-recombinant) form of the cell or express native genes that are otherwise abnormally expressed, under expressed or not expressed at all as a result of deliberate human intervention. “Recombination”, “recombining” or generating a“recombined” nucleic acid is generally the assembly of two or more nucleic acid fragments wherein the assembly gives rise to a chimeric gene.

[0204] As used herein, a“flanking sequence” refers to any sequence that is either upstream or downstream of the sequence being discussed ( e.g ., for genes A-B-C, gene B is flanked by the A and C gene sequences). In certain embodiments, the incoming sequence is flanked by a homology box on each side. In another embodiment, the incoming sequence and the homology boxes comprise a unit that is flanked by staffer sequence on each side. In some embodiments, a flanking sequence is present on only a single side (either 3' or 5'), but in preferred embodiments, it is on each side of the sequence being flanked. The sequence of each homology box is homologous to a sequence in the Bacillus chromosome. These sequences direct where in the Bacillus chromosome the new construct gets integrated and what part of the Bacillus chromosome will be replaced by the incoming sequence. In other embodiments, the 5' and 3' ends of a selective marker are flanked by a polynucleotide sequence comprising a section of the inactivating chromosomal segment. In some embodiments, a flanking sequence is present on only a single side (either 3' or 5'), while in other embodiments, it is present on each side of the sequence being flanked.

[0205] As used herein, the term“stuffer sequence” refers to any extra DNA that flanks homology boxes (typically vector sequences). However, the term encompasses any non- homologous DNA sequence. Not to be limited by any theory, a stuffer sequence provides a non-critical target for a cell to initiate DNA uptake.

II. GlcT ANTITERMINATION PROTEIN

[0206] As described below in the Examples section, Applicant performed routine whole host mutagenesis (NTG) to create a pool of B. licheniformis mutants (i.e., modified B. licheniformis daughter cells) and used routine screening procedures to identify such modified B. licheniformis daughter cells capable of producing increased amounts of industrially relevant proteins of interest (e.g., heterologous enzymes, endogenous enzymes). More particularly, Applicant identified a modified Bacillus licheniformis (daughter) cell comprising a single nucleotide polymorphism (SNP) in a gene encoding a variant GlcT protein, which modified B. licheniformis (daughter) cell was capable of producing increased amounts of amylase protein, relative to a parental B. licheniformis cell comprising a gene encoding a wild-type GlcT protein (i.e.. when the modified and parental B. licheniformis cells are cultivated under similar conditions).

[0207] As generally described in Schmalisch et al. (2003), the Bacillus suhtilis GlcT protein is a member of the BglG family of transcriptional anti-terminators, which anti-terminators comprise an N-terminal RNA binding domain (about 60 amino acids), and two reiterated phosphotransferase system (PTS) regulation domains (PRDs; PRD-I and PRD-II), that modulate the regulatory output of the protein in response to the availability of the inducer (Manival et al., 1997; Stulke et al., 1998). For example, in Escherichia coli, Bacillus subtilis, and several other bacteria, glucose is taken up and concomitantly phosphorylated by the phosphoenolpyruvate: sugar phosphotransferase system (PTS) (Postma et al., 1993). The phosphotransferase system (PTS) is made up of two general energy-coupling proteins, Enzyme I (El) and HPr, and several multi-domain sugar specific permeases (e.g., Enzyme II, (Eli)), which may exist as individual proteins or fused in a single polypeptide.

[0208] For example, in B. subtilis, all domains of the glucose permease (Eli) are fused to form a single polypeptide, with the domain arrangement (EIIC)- (EIIB)-(EIIA) (e.g., see, Postma el al.. 1993; Stulke and Hillen, 2000). Furthermore, it was long considered that the genes encoding the components of the glucose PTS are constitutively expressed in bacteria. Although this is the case for the ptsl and ptsH genes encoding the general proteins, the ptsG gene encoding the glucose-specific permease (EII ^Glc ) is induced by glucose in both E. coli and B. subtilis (Postma et al, 1993; Stulke and Hillen, 2000; Plumbridge, 2002.) In B. subtilis, glucose induction of ptsG expression is mediated by transcriptional anti-termination. For example, in the absence of glucose, transcription initiated at the ptsG promoter is terminated in the leader region of the mRNA. If glucose is present, the GlcT anti-termination protein is active (i.e.. a dimer), and prevents transcription termination by binding to the RNA anti-terminator (RAT) sequence, which overlaps the terminator. The binding of GlcT to the RAT is thought to stabilize the RAT structure and to prevent formation of the terminator (Stulke et al., 1997; Langbein el al., 1999).

[0209] Without wishing to be bound by any particular theory, mechanism, or mode of action, Applicant surprisingly discovered that modified B. licheniformis (daughter) cells of the disclosure, comprising a gene or ORF thereof encoding a variant GlcT protein, were capable of producing increased amounts of industrially relevant proteins of interest. More particularly, Applicant identified a modified Bacillus licheniformis (daughter) cell comprising a single nucleotide polymorphism (SNP) in a gene encoding a variant GlcT protein, which modified B. licheniformis (daughter) cell was capable of producing increased amounts of amylase protein, relative to a parental B. licheniformis cell comprising a gene encoding a wild- type GlcT protein (i.e.. when the modified and parental B. licheniformis cells are cultivated under identical conditions).

[0210] For example, FIG. 1 A shows a nucleic acid sequence alignment of a parental B. licheniformis ORF (SEQ ID NO: 22) encoding a wild-type GlcT protein (SEQ ID NO: 82), relative to the modified B. licheniformis ORF (SEQ ID NO: 56) encoding the variant GlcT protein (SEQ ID NO: 55). As shown in FIG. 1A, the two aligned ORF sequences (SEQ ID NO: 22 vs. SEQ ID NO: 56), differ by a SNP at nucleotide position 199, wherein position 199 of SEQ ID NO: 22 comprises a cytosine (C) and position 199 of SEQ ID NO: 56 comprises a thymine (T) ( e.g ., see FIG. 1A black boxed nucleotides (C) and (T) at position 199). Similarly, FIG. 1B shows an alignment of the encoded wild-type GlcT protein (SEQ ID NO: 82) and the encoded variant GlcT protein (SEQ ID NO: 55), wherein the (C) to (T) SNP at position 199 of SEQ ID NO: 56 (see, FIG. 1A), results in a leucine (L) to phenylalanine (F) substitution at amino acid residue position 67 of SEQ ID NO: 55 (e.g., see FIG. 1B, black boxed (L) and (F) amino acids at residue position 67 of SEQ ID NO: 22 and SEQ ID NO: 55, respectively).

[0211] Applicant further performed a BLAST protein sequence search, alignment and analysis thereof using the wild-type GlcT protein sequence of SEQ ID NO: 82, which analysis revealed that the leucine (L) amino acid at position 67 of SEQ ID NO: 82 is highly conserved among Bacillus sp. cells. Likewise, the sequence identity of the full length GlcT protein sequence is highly conserved (e.g., 80-100% amino acid sequence identity) among Bacillus sp. cells. Thus, in certain embodiments, allele glcTl encodes a GlcT protein comprising about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 55 and comprises a phenylalanine (F) at amino acid residue position 67 of SEQ ID NO: 55. III. RghR2 _rest B. LICHENIFORMIS CELLS

[0212] As generally set forth above in Section II, certain embodiments of the disclosure are related to modified Bacillus (host) cells (i.e.. comprising a modified glcT gene encoding a variant GlcT protein, e.g., comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55), wherein the modified cells produce an increased amount of a protein of interest (POI) relative to a parental Bacillus cell producing the same POI. In certain related embodiments, a modified Bacillus cell of the disclosure is a modified B. licheniformis cell, comprising a restored rghR2 gene ( rghR2 _rest ) described and set forth in U.S. Provisional Patent Application Serial No. 62/463,268.

[0213] For example, in certain embodiments of the instant disclosure, a modified Bacillus licheniformis cell comprises a restored rghR2 gene comprising 90% sequence identity to the rghR2 gene of SEQ ID NO: 61. In other embodiments, a modified B. licheniformis cell comprises a restored rghR2 gene comprising 95% sequence identity to the rghR2 gene of SEQ ID NO: 61. In yet other embodiments, a modified B. licheniformis cell comprises a restored rghR2 gene of SEQ ID NO: 61.

[0214] In other embodiments, a modified B. licheniformis cell comprises a restored rghR2 gene encoding a RghR2 protein comprising 90% sequence identity to the RghR2 protein of SEQ ID NO: 84. In certain other embodiments, a modified B. licheniformis cell comprises a restored rghR2 gene encoding a RghR2 protein comprising 95% sequence identity to the RghR2 protein of SEQ ID NO: 84. In yet other embodiments, a modified B. licheniformis cell comprises a restored rghR2 gene encoding a RghR2 protein of SEQ ID NO: 84. Thus, certain embodiments of the disclosure are related to modified B. licheniformis cells comprising a restored rghR2 ( rghR2 _rest ) gene and allele glcTl.

IV MODIFIED B. SUBTILISAPRE 5'-UTR NUCLEIC ACID SEQEUCNES

[0215] As generally set forth above, certain embodiments the disclosure are related to modified Bacillus (host) cells comprising allele glcTl _, where in the modified Bacillus cells are capable of producing increased amounts of endogenous and/or heterologous proteins of interest relative to a parental Bacillus cell comprising a native/wild-type glcT gene. Thus, in certain related embodiments, the Bacillus parental cell and modified daughter cells thereof (e.g., comprising allele glcTl) are transformed with an expression construct encoding a protein of interest. For example, in certain embodiments, parental and modified Bacillus cells are transformed with an expression construct encoding a POI (e.g., an amylase, a protease, a lipase, etc).

[0216] Thus, in certain related embodiments, a nucleic acid sequence (e.g., an ORF) encoding a POI is operably linked to a modified B. subtilis aprE 5 '-untranslated region (mod-5 '-UTR) sequence (SEQ ID NO: 63). For example, Applicant’s U.S. Provisional Patent Application Serial No. 62/558,304, filed September 13, 2017 (incorporated herein by reference in its entirety) discloses and fully describes such mod-5 '-UTR sequences, vectors thereof, modified host cells thereof and the like.

[0217] More particularly, as presented in Example 7 of the instant disclosure, Applicant tested the effect of a modified aprE 5' untranslated region (mod-5 '-UTR) sequence on expression of genes encoding proteins of interest in Bacillus cells, (e.g., by constructing a-amylase expression cassettes comprising either the wild-type B. subtilis aprE 5'-UTR (SEQ ID NO: 62) or a modified aprE 5'-UTR (SEQ ID NO: 63). Thus, the Example 7 describes the creation of Bacillus host cells for the assessment of various (modified) 5'-UTR constructs, and their impact/influence on the production of proteins of interest when such modified 5'-UTR constructs are operably linked to an upstream (5') promoter and a downstream (3') open reading frame encoding the protein of interest.

[0218] For example, parental and modified B. licheniformis (daughter) cells BF63, BF62, and BF169 (see. Table 17 and Table 18), comprising a plasmid (pBL.ComK) carrying a xylose-inducible comK expression cassette (SEQ ID NO: 50) were constructed. More particularly, as described in the Examples section below, either the wild-type (WT) 5'-UTR expression construct (SEQ ID NO: 64) or the modified 5'-UTR expression construct (SEQ ID NO: 65) were constructed and tested, wherein each expression cassette (i.e., SEQ ID NO: 64 or SEQ ID NO: 65) comprised (in the 5' to 3' direction) the same 5' catH homology arm (SEQ ID NO: 66), catH gene (SEQ ID NO: 67) and spoVGrrnlp hybrid promoter (SEQ ID NO: 68), operably linked to either the WT-5'-UTR (SEQ ID NO: 62) or the mod-5'-UTR (SEQ ID NO: 63). In addition, the 5'-UTR was operably linked to the DNA encoding the lat signal sequence (SEQ ID NO: 69), followed by DNA (ORF) encoding a variant G. stearothermophilus a-amylase (SEQ ID NO: 70). The 3' end of the DNA (ORF) encoding the variant G. stearothermophilus a-amylase (SEQ ID NO: 70), was operably linked to the lat terminator (SEQ ID NO: 71), which was operably linked to the 3' catH homology arm (SEQ ID NO: 72).

V. MOLECULAR BIOLOGY

[0219] As generally set forth above, certain embodiments of the disclosure are related to modified Bacillus (daughter) cells derived from parental Bacillus cells. More particularly, certain embodiments of the disclosure are related to modified Bacillus (daughter) cells and methods thereof for producing and constructing such modified Bacillus (host) cells (e.g., protein production host cells, cell factories) having increased protein production capabilities, increased secondary metabolite production capabilities and the like.

[0220] More specifically, certain embodiments of the disclosure are directed to mutants of a parental Bacillus cell comprising a glcT gene encoding a variant GlcT protein comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. Certain other embodiments of the disclosure are related to modified Bacillus cells derived from parental Bacillus cells comprising a wild-type glcT gene encoding a GlcT protein comprising a leucine (L) at amino acid position 67 (F67) of SEQ ID NO: 82, wherein the modified Bacillus cells comprise an edited (modified) glcT gene encoding a variant GlcT protein of SEQ ID NO: 55. Certain other embodiments are related to modified Bacillus (daughter) cells comprising an introduced polynucleotide encoding a variant GlcT protein comprising of SEQ ID NO: 55, comprising a phenylalanine (F) at amino acid position 67 (F67) of SEQ ID NO: 55. In other embodiments, modified Bacillus cells of the disclosure comprise an inactivated (endogenous) native chromosomal glcT gene (i.e., encoding a GlcT protein comprising at least 95% sequence identity to SEQ ID NO: 82 and comprising a leucine (L) at amino acid position 67 (L67) of SEQ ID NO: 55).

[0221] In certain other embodiments, a modified Bacillus licheniformis cell of the disclosure comprising and expressing a polynucleotide encoding a variant GlcT protein, further comprises a modification of an rghR2 gene which encodes a RghR2 protein comprising 90% sequence identity to SEQ ID NO: 84. In other embodiments the disclosure is related to modified B. licheniformis cells derived from parental B. licheniformis cells comprising a rghR2 gene encoding a RghR2 protein of SEQ ID NO: 83, wherein the modified cells comprise a restored rghR2 gene encoding a RghR2 protein of SEQ ID NO: 84.

[0222] Thus, certain embodiments of the disclosure provide compositions and methods for genetically modifying (altering) a parental Bacillus cell of the disclosure to generate modified Bacillus cells thereof, and more particularly, modified Bacillus cells which produce an increased amount of endogenous and/or heterologous proteins of interest relative to (unmodified) parental B. licheniformis cells.

[0223] Thus, certain embodiments of the disclosure are directed to methods for genetically modifying Bacillus cells, wherein the modification comprises (a) the introduction, substitution, or removal of one or more nucleotides in a gene (or an ORF thereof), or the introduction, substitution, or removal of one or more nucleotides in a regulatory element required for the transcription or translation of the gene or ORF thereof, (b) a gene disruption, (c) a gene conversion, (d) a gene deletion, (e) a gene down-regulation, (f) site specific mutagenesis and/or (g) random mutagenesis.

[0224] In certain embodiments, a modified Bacillus cell of the disclosure is constructed by reducing or eliminating the expression of a gene set forth above, using methods well known in the art, for example, insertions, disruptions, replacements, or deletions. The portion of the gene to be modified or inactivated may be, for example, the coding region or a regulatory element required for expression of the coding region. An example of such a regulatory or control sequence may be a promoter sequence or a functional part thereof, (i.e., a part which is sufficient for affecting expression of the nucleic acid sequence). Other control sequences for modification include, but are not limited to, a leader sequence, a pro-peptide sequence, a signal sequence, a transcription terminator, a transcriptional activator and the like. [0225] In certain other embodiments a modified Bacillus cell is constructed by gene deletion to eliminate or reduce the expression of at least one of the aforementioned genes of the disclosure. Gene deletion techniques enable the partial or complete removal of the gene(s), thereby eliminating their expression, or expressing a non-functional (or reduced activity) protein product. In such methods, the deletion of the gene(s) may be accomplished by homologous recombination using a plasmid that has been constructed to contiguously contain the 5' and 3' regions flanking the gene. The contiguous 5' and 3' regions may be introduced into a Bacillus cell, for example, on a temperature-sensitive plasmid, such as rE194, in association with a second selectable marker at a permissive temperature to allow the plasmid to become established in the cell. The cell is then shifted to a non-permissive temperature to select for cells that have the plasmid integrated into the chromosome at one of the homologous flanking regions. Selection for integration of the plasmid is effected by selection for the second selectable marker. After integration, a recombination event at the second homologous flanking region is stimulated by shifting the cells to the permissive temperature for several generations without selection. The cells are plated to obtain single colonies and the colonies are examined for loss of both selectable markers (see, e.g.. Perego, 1993). Thus, a person of skill in the art may readily identify nucleotide regions in the gene’s coding sequence and/or the gene’s non-coding sequence suitable for complete or partial deletion.

[0226] In other embodiments, a modified Bacillus cell of the disclosure is constructed by introducing, substituting, or removing one or more nucleotides in the gene or a regulatory element required for the transcription or translation thereof. For example, nucleotides may be inserted or removed so as to result in the introduction of a stop codon, the removal of the start codon, or a frame-shift of the open reading frame. Such a modification may be accomplished by site-directed mutagenesis or PCR generated mutagenesis in accordance with methods known in the art (e.g., see, Botstein and Shortle, 1985; Lo et al., 1985; Higuchi et al., 1988; Shimada, 1996; Ho et al, 1989; Horton et al, 1989 and Sarkar and Sommer, 1990). Thus, in certain embodiments, a gene of the disclosure is inactivated by complete or partial deletion.

[0227] In another embodiment, a modified Bacillus cell is constructed by the process of gene conversion (e.g., see Iglesias and Trautner, 1983). For example, in the gene conversion method, a nucleic acid sequence corresponding to the gene(s) is mutagenized in vitro to produce a defective nucleic acid sequence, which is then transformed into the parental Bacillus cell to produce a defective gene. By homologous recombination, the defective nucleic acid sequence replaces the endogenous gene. It may be desirable that the defective gene or gene fragment also encodes a marker which may be used for selection of transformants containing the defective gene. For example, the defective gene may be introduced on a non-replicating or temperature- sensitive plasmid in association with a selectable marker. Selection for integration of the plasmid is effected by selection for the marker under conditions not permitting plasmid replication. Selection for a second recombination event leading to gene replacement is effected by examination of colonies for loss of the selectable marker and acquisition of the mutated gene (Perego, 1993). Alternatively, the defective nucleic acid sequence may contain an insertion, substitution, or deletion of one or more nucleotides of the gene, as described below.

[0228] In other embodiments, a modified Bacillus cell is constructed by established anti-sense techniques using a nucleotide sequence complementary to the nucleic acid sequence of the gene (Parish and Stoker, 1997). More specifically, expression of the gene by a Bacillus cell may be reduced (down-regulated) or eliminated by introducing a nucleotide sequence complementary to the nucleic acid sequence of the gene, which may be transcribed in the cell and is capable of hybridizing to the mRNA produced in the cell. Under conditions allowing the complementary anti-sense nucleotide sequence to hybridize to the mRNA, the amount of protein translated is thus reduced or eliminated. Such anti-sense methods include, but are not limited to RNA interference (RNAi), small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides, and the like, all of which are well known to the skilled artisan.

[0229] In other embodiments, a modified Bacillus cell is produced/constructed via CRISPR-Cas9 editing. For example, a gene encoding a GlcT protein can be edited or disrupted (or deleted or down-regulated) by means of nucleic acid guided endonucleases, that find their target DNA by binding either a guide RNA (e.g., Cas9) and Cpfl or a guide DNA (e.g., NgAgo), which recruits the endonuclease to the target sequence on the DNA, wherein the endonuclease can generate a single or double stranded break in the DNA. This targeted DNA break becomes a substrate for DNA repair, and can recombine with a provided editing template to disrupt or delete the gene. For example, the gene encoding the nucleic acid guided endonuclease (for this purpose Cas9 from S. pyogenes) or a codon optimized gene encoding the Cas9 nuclease is operably linked to a promoter active in the Bacillus cell and a terminator active in Bacillus cell, thereby creating a Bacillus Cas9 expression cassette. Likewise, one or more target sites unique to the gene of interest are readily identified by a person skilled in the art. For example, to build a DNA construct encoding a gRNA -directed to a target site within the gene of interest, the variable targeting domain (VT) will comprise nucleotides of the target site which are 5' of the (PAM) proto-spacer adjacent motif (TGG), which nucleotides are fused to DNA encoding the Cas9 endonuclease recognition domain for S. pyogenes Cas9 (CER). The combination of the DNA encoding a VT domain and the DNA encoding the CER domain thereby generate a DNA encoding a gRNA. Thus, a Bacillus expression cassette for the gRNA is created by operably linking the DNA encoding the gRNA to a promoter active in Bacillus cells and a terminator active in Bacillus cells.

[0230] In certain embodiments, the DNA break induced by the endonuclease is repaired/replaced with an incoming sequence. For example, to precisely repair the DNA break generated by the Cas9 expression cassette and the gRNA expression cassette described above, a nucleotide editing template is provided, such that the DNA repair machinery of the cell can utilize the editing template. For example, about 500bp 5' of targeted gene can be fused to about 500bp 3' of the targeted gene to generate an editing template, which template is used by the Bacillus host’s machinery to repair the DNA break generated by the RGEN.

[0231] The Cas9 expression cassette, the gRNA expression cassette and the editing template can be co delivered to filamentous fungal cells using many different methods (e.g., protoplast fusion, electroporation, natural competence, or induced competence). The transformed cells are screened by PCR amplifying the target gene locus, by amplifying the locus with a forward and reverse primer. These primers can amplify the wild-type locus or the modified locus that has been edited by the RGEN. These fragments are then sequenced using a sequencing primer to identify edited colonies.

[0232] In yet other embodiments, a modified Bacillus cell is constructed by random or specific mutagenesis using methods well known in the art, including, but not limited to, chemical mutagenesis (see, e.g., Hopwood, 1970) and transposition (see, e.g., Youngman et ak, 1983). Modification of the gene may be performed by subjecting the parental cell to mutagenesis and screening for mutant cells in which expression of the gene has been reduced or eliminated. The mutagenesis, which may be specific or random, may be performed, for example, by use of a suitable physical or chemical mutagenizing agent, use of a suitable oligonucleotide, or subjecting the DNA sequence to PCR generated mutagenesis. Furthermore, the mutagenesis may be performed by use of any combination of these mutagenizing methods.

[0233] Examples of a physical or chemical mutagenizing agent suitable for the present purpose include ultraviolet (UV) irradiation, hydroxylamine, N-methyl-N'-nitro-N-nitrosoguanidine (MNNG), N-methyl- N'-nitrosoguanidine (NTG), O-methyl hydroxylamine, nitrous acid, ethyl methane sulphonate (EMS), sodium bisulphite, formic acid, and nucleotide analogues. When such agents are used, the mutagenesis is typically performed by incubating the parental cell to be mutagenized in the presence of the mutagenizing agent of choice under suitable conditions, and selecting for mutant cells exhibiting reduced or no expression of the gene.

[0234] In certain other embodiments, a modified Bacillus cell comprises a deletion of an endogenous gene. In other embodiments, a modified Bacillus cell comprises a disruption of an endogenous gene. In certain embodiments, a polynucleotide disruption cassette of the disclosure comprises a marker gene.

[0235] In other embodiments, a modified Bacillus cell comprises a down-regulated endogenous gene. For example, in certain embodiments, down-regulating one or more genes set forth above comprises deleting or disrupting the gene’s upstream or downstream regulatory elements.

[0236] PCT Publication No. W02003/083125 discloses methods for modifying Bacillus cells, such as the creation of Bacillus deletion strains and DNA constructs using PCR fusion to bypass E. coli.

[0237] PCT Publication No. W02002/14490 discloses methods for modifying Bacillus cells including (1) the construction and transformation of an integrative plasmid (pComK), (2) random mutagenesis of coding sequences, signal sequences and pro-peptide sequences, (3) homologous recombination, (4) increasing transformation efficiency by adding non-homologous flanks to the transformation DNA, (5) optimizing double cross-over integrations, (6) site directed mutagenesis and (7) marker-less deletion.

[0238] Those of skill in the art are well aware of suitable methods for introducing polynucleotide sequences into bacterial cells (e.g., E. coli and Bacillus spp.) (e.g., Ferrari et al, 1989; Saunders et al, 1984; Hoch et al, 1967; Mann et al, 1986; Holubova, 1985; Chang et al., 1979; Vorobjeva et al., 1980; Smith et al., 1986; Fisher et. al., 1981 and McDonald, 1984). Indeed, such methods as transformation including protoplast transformation and congression, transduction, and protoplast fusion are known and suited for use in the present disclosure. Methods of transformation are particularly preferred to introduce a DNA construct of the present disclosure into a host cell.

[0239] In addition to commonly used methods, in some embodiments, host cells are directly transformed ( i.e ., an intermediate cell is not used to amplify, or otherwise process, the DNA construct prior to introduction into the host cell). Introduction of the DNA construct into the host cell includes those physical and chemical methods known in the art to introduce DNA into a host cell, without insertion into a plasmid or vector. Such methods include, but are not limited to, calcium chloride precipitation, electroporation, naked DNA, liposomes and the like. In additional embodiments, DNA constructs are co-transformed with a plasmid without being inserted into the plasmid. In further embodiments, a selective marker is deleted or substantially excised from the modified Bacillus strain by methods known in the art (e.g., Stahl et al, 1984 and Palmeros et al., 2000). In some embodiments, resolution of the vector from a host chromosome leaves the flanking regions in the chromosome, while removing the indigenous chromosomal region.

[0240] Promoters and promoter sequence regions for use in the expression of genes, open reading frames (ORFs) thereof and/or variant sequences thereof in Bacillus cells are generally known on one of skill in the art. Promoter sequences of the disclosure of the disclosure are generally chosen so that they are functional in the Bacillus cells (e.g., B. licheniformis cells, B. subtilis cells and the like). Certain exemplary Bacillus promoter sequences are presented in Table 6. Likewise, promoters useful for driving gene expression in Bacillus cells include, but are not limited to, the B. subtilis alkaline protease (aprE) promoter (Stahl et al, 1984), the a-amylase promoter of B. subtilis (Yang et al, 1983), the a-amylase promoter of B. amyloliquefaciens (Tarkinen et al, 1983), the neutral protease (nprE) promoter from B. subtilis (Yang et al., 1984), a mutant aprE promoter (PCT Publication No. W02001/51643) or any other promoter from B licheniformis or other related Bacilli. In certain other embodiments, the promoter is a ribosomal protein promoter or a ribosomal RNA promoter (e.g., the rml promoter) disclosed in U.S. Patent Publication No. 2014/0329309. Methods for screening and creating promoter libraries with a range of activities (promoter strength) in Bacillus cells is describe in PCT Publication No. W02003/089604. VI. CULTURING BACILLUS CELLS FOR PRODUCTION OF A PROTEIN OF INTEREST

[0241] In other embodiments, the present disclosure provides methods for increasing the protein productivity of a modified bacterial cell, as compared (i.e., relative) to an unmodified (parental) cell. In certain embodiments, the instant disclosure is directed to methods of producing a protein of interest (POI) comprising fermenting/cultivating a modified bacterial cell, wherein the modified cell secrets the POI into the culture medium. Fermentation methods well known in the art can be applied to ferment the modified and unmodified Bacillus cells of the disclosure.

[0242] In some embodiments, the cells are cultured under batch or continuous fermentation conditions. A classical batch fermentation is a closed system, where the composition of the medium is set at the beginning of the fermentation and is not altered during the fermentation. At the beginning of the fermentation, the medium is inoculated with the desired organism(s). In this method, fermentation is permitted to occur without the addition of any components to the system. Typically, a batch fermentation qualifies as a“batch” with respect to the addition of the carbon source, and attempts are often made to control factors such as pH and oxygen concentration. The metabolite and biomass compositions of the batch system change constantly up to the time the fermentation is stopped. Within typical batch cultures, cells can progress through a static lag phase to a high growth log phase, and finally to a stationary phase, where growth rate is diminished or halted. If untreated, cells in the stationary phase eventually die. In general, cells in log phase are responsible for the bulk of production of product.

[0243] A suitable variation on the standard batch system is the“fed-batch fermentation” system. In this variation of a typical batch system, the substrate is added in increments as the fermentation progresses. Fed-batch systems are useful when catabolite repression likely inhibits the metabolism of the cells and where it is desirable to have limited amounts of substrate in the medium. Measurement of the actual substrate concentration in fed-batch systems is difficult and is therefore estimated on the basis of the changes of measurable factors, such as pH, dissolved oxygen and the partial pressure of waste gases, such as CO2. Batch and fed-batch fermentations are common and known in the art.

[0244] Continuous fermentation is an open system where a defined fermentation medium is added continuously to a bioreactor, and an equal amount of conditioned medium is removed simultaneously for processing. Continuous fermentation generally maintains the cultures at a constant high density, where cells are primarily in log phase growth. Continuous fermentation allows for the modulation of one or more factors that affect cell growth and/or product concentration. For example, in one embodiment, a limiting nutrient, such as the carbon source or nitrogen source, is maintained at a fixed rate and all other parameters are allowed to moderate. In other systems, a number of factors affecting growth can be altered continuously while the cell concentration, measured by media turbidity, is kept constant. Continuous systems strive to maintain steady state growth conditions. Thus, cell loss due to medium being drawn off should be balanced against the cell growth rate in the fermentation. Methods of modulating nutrients and growth factors for continuous fermentation processes, as well as techniques for maximizing the rate of product formation, are well known in the art of industrial microbiology.

[0245] Thus, in certain embodiments, a POI produced by a transformed (modified) host cell may be recovered from the culture medium by conventional procedures including separating the host cells from the medium by centrifugation or filtration, or if necessary, disrupting the cells and removing the supernatant from the cellular fraction and debris. Typically, after clarification, the proteinaceous components of the supernatant or filtrate are precipitated by means of a salt, e.g., ammonium sulfate. The precipitated proteins are then solubilized and may be purified by a variety of chromatographic procedures, e.g., ion exchange chromatography, gel filtration.

VII. PROTEINS OF INTEREST PRODUCED BY MODIFIED (HOST) CELLS

[0246] A protein of interest (POI) of the instant disclosure can be any endogenous or heterologous protein, and it may be a variant of such a POI. The protein can contain one or more disulfide bridges or is a protein whose functional form is a monomer or a multimer, i.e.. the protein has a quaternary structure and is composed of a plurality of identical (homologous) or non-identical (heterologous) subunits, wherein the POI or a variant POI thereof is preferably one with properties of interest.

[0247] For example, as set forth in the Examples below, the modified Bacillus cells of the disclosure produce an increased amount of endogenous and/or heterologous proteins of interests. Thus, in certain embodiments, a modified cell of the disclosure expresses an endogenous POI, a heterologous POI or a combination of one or more of such POIs. For example, in certain embodiments, a modified Bacillus (daughter) cell of the disclosure produces an increased amount of an endogenous POI relative to a parental Bacillus cell. In other embodiments, a modified Bacillus (daughter) cell of the disclosure produces an increased amount of a heterologous POI relative to a parental Bacillus cell.

[0248] Thus, in certain embodiments, a modified Bacillus (daughter) cell of the disclosure produces an increased amount of a POI relative to a parental Bacillus (control) cell, wherein the increased amount of the POI is at least about a 0.01% increase, at least about a 0.10% increase, at least about a 0.50% increase, at least about a 1.0% increase, at least about a 2.0% increase, at least about a 3.0% increase, at least about a 4.0% increase, at least about a 5.0% increase, or an increase greater than 5.0%. In certain embodiments, the increased amount of the POI is determined by assaying enzymatic activity and/or by assaying/quantifying the specific productivity (Qp) thereof. Likewise, one skilled in the art may utilize other routine methods and techniques known in the art for detecting, assaying, measuring, etc. the expression or production of one or more proteins of interest. [0249] In certain embodiments, a modified Bacillus cell of the disclosure exhibits an increased specific productivity (Qp) of a POI relative the (unmodified) parental Bacillus cell. For example, the detection of specific productivity (Qp) is a suitable method for evaluating protein production. The specific productivity (Qp) can be determined using the following equation:

“Qp = gP/gDCW*hr”

wherein,“gP” is grams of protein produced in the tank;“gDCW” is grams of dry cell weight (DCW) in the tank and“hr” is fermentation time in hours from the time of inoculation, which includes the time of production as well as growth time.

[0250] Thus, in certain other embodiments, a modified Bacillus cell of the disclosure comprises a specific productivity (Qp) increase of at least about 0.1%, at least about 1%, at least about 5%, at least about 6%, at least about 7%, at least about 8%, at least about 9%, or at least about 10% or more as compared to the unmodified (parental) cell.

[0251] In certain embodiments, a POI or a variant POI thereof is selected from the group consisting of acetyl esterases, aminopeptidases, amylases, arabinases, arabinof iranosidases, carbonic anhydrases, carboxypeptidases, catalases, cellulases, chitinases, chymosins, cutinases, deoxyribonucleases, epimerases, esterases, a-galactosidases, b-galactosidases, a-glucanases, glucan lysases, endo^-glucanases, glucoamylases, glucose oxidases, a-glucosidases, b-glucosidases, glucuronidases, glycosyl hydrolases, hemicellulases, hexose oxidases, hydrolases, invertases, isomerases, laccases, ligases, lipases, lyases, mannosidases, oxidases, oxidoreductases, pectate lyases, pectin acetyl esterases, pectin depolymerases, pectin methyl esterases, pectinolytic enzymes, perhydrolases, polyol oxidases, peroxidases, phenoloxidases, phytases, polygalacturonases, proteases, peptidases, rhamno-galacturonases, ribonucleases, transferases, transport proteins, transglutaminases, xylanases, hexose oxidases, and combinations thereof.

[0252] Thus, in certain embodiments, a POI or a variant POI thereof is an enzyme selected from Enzyme Commission (EC) Number EC 1, EC 2, EC 3, EC 4, EC 5 or EC 6.

[0253] For example, in certain embodiments a POI is an oxidoreductase enzyme, including, but not limited to, an EC 1 (oxidoreductase) enzyme selected from EC 1.10.3.2 (e.g., a laccase), EC 1.10.3.3 (e.g., L- ascorbate oxidase), EC 1.1.1.1 (e.g., alcohol dehydrogenase), EC 1.11.1.10 (e.g., chloride peroxidase), EC 1.11.1.17 (e.g., peroxidase), EC 1.1.1.27 (e.g., L-lactate dehydrogenase), EC 1.1.1.47 (e.g., glucose 1- dehydrogenase), EC 1.1.3.X (e.g., glucose oxidase), EC 1.1.3.10 (e.g., pyranose oxidase), EC 1.13.1 l.X (e.g., dioxygenase), EC 1.13.11.12 (e.g., lineolate l3S-lipozygenase), EC 1.1.3.13 (e.g., alcohol oxidase), EC 1.14.14.1 (e.g., monooxygenase), EC 1.14.18.1 (e.g., monophenol monooxigenase) EC 1.15.1.1 (e.g., superoxide dismutase), EC 1.1.5.9 (formerly EC 1.1.99.10, e.g., glucose dehydrogenase), EC 1.1.99.18 (e.g., cellobiose dehydrogenase), EC 1.1.99.29 (e.g., pyranose dehydrogenase), EC 1.2. l.X (e.g., fatty acid reductase), EC 1.2.1.10 (e.g., acetaldehyde dehydrogenase), EC 1.5.3.X (e.g., fructosyl amine reductase), EC 1.8. l .X (e.g., disulfide reductase) and EC 1.8.3.2 (e.g., thiol oxidase).

[0254] In certain embodiments a POI is a transferase enzyme, including, but not limited to, an EC 2 (transferase) enzyme selected from EC 2.3.2.13 (e.g., transglutaminase), EC 2.4. l .X (e.g., hexosyltransferase), EC 2.4.1.40 (e.g., altemasucrase), EC 2.4.1.18 (e.g., 1,4 alpha-glucan branching enzyme), EC 2.4.1.19 (e.g., cyclomaltodextrin glucanotransferase), EC 2.4.1.2 (e.g., dextrin dextranase), EC 2.4.1.20 (e.g., cellobiose phosphorylase), EC 2.4.1.25 (e.g., 4-alpha-glucanotransferase), EC 2.4.1.333 (e.g., l,2-beta-oligoglucan phosphor transferase), EC 2.4.1.4 (e.g., amylosucrase), EC 2.4.1.5 (e.g., dextransucrase), EC 2.4.1.69 (e.g., galactoside 2-alpha-L-fucosyl transferase), EC 2.4.1.9 (e.g., inulosucrase), EC 2.7.1.17 (e.g., xylulokinase), EC 2.7.7.89 (formerly EC 3.1.4.15, e.g., [glutamine synthetase] -adenylyl-L-tyrosine phosphorylase), EC 2.7.9.4 (e.g., alpha glucan kinase) and EC 2.7.9.5 (e.g., phosphoglucan kinase).

[0255] In other embodiments a POI is a hydrolase enzyme, including, but not limited to, an EC 3 (hydrolase) enzyme selected from EC 3.1.X.X (e.g., an esterase), EC 3.1.1.1 (e.g., pectinase), EC 3.1.1.14 (e.g., chlorophyllase), EC 3.1.1.20 (e.g., tannase), EC 3.1.1.23 (e.g., glycerol-ester acylhydrolase), EC 3.1.1.26 (e.g., galactolipase), EC 3.1.1.32 (e.g., phospholipase Al), EC 3.1.1.4 (e.g., phospholipase A2), EC 3.1.1.6 (e.g., acetylesterase), EC 3.1.1.72 (e.g., acetylxylan esterase), EC 3.1.1.73 (e.g., feruloyl esterase), EC 3.1.1.74 (e.g., cutinase), EC 3.1.1.86 (e.g., rhamnogalacturonan acetylesterase), EC 3.1.1.87 (e.g., fumosin B l esterase), EC 3.1.26.5 (e.g., ribonuclease P), EC 3.1.3.X (e.g., phosphoric monoester hydrolase), EC 3.1.30.1 (e.g., Aspergillus nuclease Sl), EC 3.1.30.2 (e.g., Serratia marcescens nuclease), EC 3.1.3.1 (e.g., alkaline phosphatase), EC 3.1.3.2 (e.g., acid phosphatase), EC 3.1.3.8 (e.g., 3-phytase), EC 3.1.4.1 (e.g., phosphodiesterase I), EC 3.1.4.11 (e.g., phosphoinositide phospholipase C), EC 3.1.4.3 (e.g., phospholipase C), EC 3.1.4.4 (e.g., phospholipase D), EC 3.1.6.1 (e.g., arylsufatase), EC 3.1.8.2 (e.g., diisopropyl-fluorophosphatase), EC 3.2.1.10 (e.g., oligo-l,6-glucosidase), EC 3.2.1.101 (e.g., mannan endo-l,6-alpha-mannosidase), EC 3.2.1.11 (e.g., alpha- l,6-glucan-6-glucanohydrolase), EC 3.2.1.131 (e.g., xylan alpha- l,2-glucuronosidase), EC 3.2.1.132 (e.g., chitosan N-acetylglucosaminohydrolase), EC 3.2.1.139 (e.g., alpha-glucuronidase), EC 3.2.1.14 (e.g., chitinase), EC 3.2.1.151 (e.g., xyloglucan-specific endo-beta-l,4-glucanase), EC 3.2.1.155 (e.g., xyloglucan-specific exo-beta- l,4-glucanase), EC 3.2.1.164 (e.g., galactan endo-l,6-beta-galactosidase), EC 3.2.1.17 (e.g., lysozyme), EC 3.2.1.171 (e.g., rhamnogalacturonan hydrolase), EC 3.2.1.174 (e.g., rhamnogalacturonan rhamnohydrolase), EC 3.2.1.2 (e.g., beta-amylase), EC 3.2.1.20 (e.g., alpha-glucosidase), EC 3.2.1.22 (e.g., alpha-galactosidase), EC 3.2.1.25 (e.g., beta-mannosidase), EC 3.2.1.26 (e.g., beta-fructofuranosidase), EC 3.2.1.37 (e.g., xylan 1,4- beta-xylosidase), EC 3.2.1.39 (e.g., glucan endo-l,3-beta-D-glucosidase), EC 3.2.1.40 (e.g., alpha-L- rhamnosidase), EC 3.2.1.51 (e.g., alpha-L-fucosidase), EC 3.2.1.52 (e.g., beta-N-Acetylhexosaminidase), EC 3.2.1.55 (e.g., alpha-N-arabinofuranosidase), EC 3.2.1.58 (e.g., glucan l,3-beta-glucosidase), EC 3.2.1.59 (e.g., glucan endo-l,3-alpha-glucosidase), EC 3.2.1.67 (e.g., galacturan l,4-alpha- galacturonidase), EC 3.2.1.68 (e.g., isoamylase), EC 3.2.1.7 (e.g., l-beta-D-fructan fructanohydrolase), EC 3.2.1.74 (e.g., glucan l,4- -glucosidase), EC 3.2.1.75 (e.g., glucan endo-l,6-beta-glucosidase), EC 3.2.1.77 (e.g., mannan l,2-(l,3)-alpha-mannosidase), EC 3.2.1.80 (e.g., fructan beta-fructosidase), EC 3.2.1.82 (e.g., exo-poly-alpha-galacturonosidase), EC 3.2.1.83 (e.g., kappa-carrageenase), EC 3.2.1.89 (e.g., arabinogalactan endo-l,4-beta-galactosidase), EC 3.2.1.91 (e.g., cellulose l,4-beta-cellobiosidase), EC 3.2.1.96 (e.g., mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase), EC 3.2.1.99 (e.g., arabinan endo-l,5-alpha-L-arabinanase), EC 3.4.X.X (e.g., peptidase), EC 3.4.1 l .X (e.g., aminopeptidase), EC 3.4.11.1 (e.g., leucyl aminopeptidase), EC 3.4.11.18 (e.g., methionyl aminopeptidase), EC 3.4.13.9 (e.g., Xaa-Pro dipeptidase), EC 3.4.14.5 (e.g., dipeptidyl-peptidase IV), EC 3.4.16. X (e.g., serine-type carboxypeptidase), EC 3.4.16.5 (e.g., carboxypeptidase C), EC 3.4.19.3 (e.g., pyroglutamyl-peptidase I), EC 3.4.21.X (e.g., serine endopeptidase), EC 3.4.21.1 (e.g., chymotrypsin), EC 3.4.21.19 (e.g., glutamyl endopeptidase), EC 3.4.21.26 (e.g., prolyl oligopeptidase), EC 3.4.21.4 (e.g., trypsin), EC 3.4.21.5 (e.g., thrombin), EC 3.4.21.63 (e.g., oryzin), EC 3.4.21.65 (e.g., thermomycolin), EC 3.4.21.80 (e.g., streptogrisin A), EC 3.4.22.X (e.g., cysteine endopeptidase), EC 3.4.22.14 (e.g., actinidain), EC 3.4.22.2 (e.g., papain), EC 3.4.22.3 (e.g., ficain), EC 3.4.22.32 (e.g., stem bromelain), EC 3.4.22.33 (e.g., fruit bromelain), EC 3.4.22.6 (e.g., chymopapain), EC 3.4.23.1 (e.g., pepsin A), EC 3.4.23.2 (e.g., pepsin B), EC 3.4.23.22 (e.g., endothiapepsin), EC 3.4.23.23 (e.g., mucorpepsin), EC 3.4.23.3 (e.g., gastricsin), EC 3.4.24. X (e.g., metalloendopeptidase), EC 3.4.24.39 (e.g., deuterolysin), EC 3.4.24.40 (e.g., serralysin), EC 3.5.1.1 (e.g., asparaginase), EC 3.5.1.11 (e.g., penicillin amidase), EC 3.5.1.14 (e.g., N-acyl-aliphatic-L-amino acid amidohydrolase), EC 3.5.1.2 (e.g., L-glutamine amidohydrolase), EC 3.5.1.28 (e.g., N-acetylmuramoyl-L- alanine amidase), EC 3.5.1.4 (e.g., amidase), EC 3.5.1.44 (e.g., protein-L-glutamine amidohydrolase), EC 3.5.1.5 (e.g., urease), EC 3.5.1.52 (e.g., peptide-N(4)-(N-acetyl-beta-glucosaminyl)asparagine amidase), EC 3.5.1.81 (e.g., N-Acyl-D-amino-acid deacylase), EC 3.5.4.6 (e.g., AMP deaminase) and EC 3.5.5.1 (e.g., nitrilase).

[0256] In other embodiments a POI is a lyase enzyme, including, but not limited to, an EC 4 (lyase) enzyme selected from EC 4.1.2.10 (e.g., mandelonitrile lyase), EC 4.1.3.3 (e.g., N-acetylneuraminate lyase), EC 4.2.1.1 (e.g., carbonate dehydratase), EC 4.2.2.- (e.g., rhamnogalacturonan lyase), EC 4.2.2.10 (e.g., pectin lyase), EC 4.2.2.22 (e.g., pectate trisaccharide-lyase), EC 4.2.2.23 (e.g., rhamnogalacturonan endolyase) and EC 4.2.2.3 (e.g., mannuronate -specific alginate lyase).

[0257] In certain other embodiments a POI is an isomerase enzyme, including, but not limited to, an EC 5 (isomerase) enzyme selected from EC 5.1.3.3 (e.g., aldose l-epimerase), EC 5.1.3.30 (e.g., D-psicose 3- epimerase), EC 5.4.99.11 (e.g., isomaltulose synthase) and EC 5.4.99.15 (e.g., (l 4)-a-D-glucan l-a-D- glucosylmutase).

[0258] In yet other embodiments, a POI is a ligase enzyme, including, but not limited to, an EC 6 (ligase) enzyme selected from EC 6.2.1.12 (e.g., 4-coumarate: coenzyme A ligase) and EC 6.3.2.28 (e.g., L-amino- acid alpha-ligase)9

[0259] Thus, in certain embodiments, industrial protease producing Bacillus host cells provide particularly preferred expression hosts. Likewise, in certain other embodiments, industrial amylase producing Bacillus host cells provide particularly preferred expression hosts.

[0260] For example, there are two general types of proteases which are typically secreted by Bacillus spp., namely neutral (or“metalloproteases”) and alkaline (or“serine”) proteases. For example, Bacillus subtilisin proteins (enzymes) are exemplary serine proteases for use in the present disclosure. A wide variety of Bacillus subtilisins have been identified and sequenced, for example, subtilisin 168, subtilisin BPN', subtilisin Carlsberg, subtilisin DY, subtilisin 147 and subtilisin 309 (e.g., WO 1989/06279 and Stahl el al, 1984). In some embodiments of the present disclosure, the modified Bacillus cells produce mutant (i.e.. variant) proteases. Numerous references provide examples of variant proteases, such as PCT Publication Nos. WO1999/20770; WO1999/20726; WO1999/20769; WO1989/06279; U.S. RE34,606; U.S. Patent Nos. 4,914,031; 4,980,288; 5,208,158; 5,310,675; 5,336,611; 5,399,283; 5,441,882; 5,482,849; 5,631,217; 5,665,587; 5,700,676; 5,741 ,694; 5,858,757; 5,880,080; 6,197,567 and 6,218,165. Thus, in certain embodiments, a modified Bacillus cells of the disclosure comprises an expression construct encoding a protease.

[0261] In certain other embodiments, a modified Bacillus cells of the disclosure comprises an expression construct encoding an amylase. A wide variety of amylase enzymes and variants thereof are known to one skilled in the art. For example, International PCT Publication NO. W02006/037484 and WO 2006/037483 describe variant a-amylases having improved solvent stability, Publication No. W01994/18314 discloses oxidatively stable a-amylase variants, Publication No. W01999/19467, W02000/29560 and W02000/60059 disclose Termamyl-like a-amylase variants, Publication No. W02008/112459 discloses a- amylase variants derived from Bacillus sp. number 707, Publication No. W01999/43794 discloses maltogenic a-amylase variants, Publication No. WO1990/11352 discloses hyper-thermostable a-amylase variants, Publication No. W02006/089107 discloses a-amylase variants having granular starch hydrolyzing activity.

[0262] In other embodiments, a POI or variant POI expressed and produced in a modified cell of the disclosure is a peptide, a peptide hormone, a growth factor, a clotting factor, a chemokine, a cytokine, a lymphokine, an antibody, a receptor, an adhesion molecule, a microbial antigen (e.g., HBV surface antigen, HPV E7, etc), variants thereof, fragments thereof and the like. Other types of proteins (or variants thereof) of interest may be those that are capable of providing nutritional value to a food or to a crop. Non-limiting examples include plant proteins that can inhibit the formation of anti-nutritive factors and plant proteins that have a more desirable amino acid composition (e.g., a higher lysine content than a non-transgenic plant).

[0263] There are various assays known to those of ordinary skill in the art for detecting and measuring activity of intrace llularly and extracellularly expressed proteins. In particular, for proteases, there are assays based on the release of acid-soluble peptides from casein or hemoglobin measured as absorbance at 280 nm or colorimetrically, using the Folin method (e.g., Bergmeyer el al, 1984). Other assays involve the solubilization of chromogenic substrates (See e.g., Ward, 1983). Other exemplary assays include succinyl- A 1 a- A 1 a- P ro - Ph e -para-n i t roan i 1 i dc assay (SAAPFpNA) and the 2,4,6-trinitrobenzene sulfonate sodium salt assay (TNBS assay). Numerous additional references known to those in the art provide suitable methods (See e.g., Wells et al, 1983; Christianson et al, 1994 and Hsia et al, 1999).

[0264] International PCT Publication No. WO2014/164777 discloses Ceralpha a-amylase activity assays useful for amylase activities described herein.

[0265] Means for determining the levels of secretion of a protein of interest in a host cell and detecting expressed proteins include the use of immunoassays with either polyclonal or monoclonal antibodies specific for the protein. Examples include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), fluorescence immunoassay (FIA), and fluorescent activated cell sorting (FACS).

EXAMPLES

[0266] Certain aspects of the present invention may be further understood in light of the following examples, which should not be construed as limiting. Modifications to materials and methods will be apparent to those skilled in the art.

EXAMPLE 1

A MUTANT BACILLUS LICHENIFORMIS DAGUHTER CELL COMPRISING A SINGLE NUCLEOTIDE POLYMORPHISM (SNP) IN A GENE ENCODING A VARIANT GlcT

PROTEIN

[0267] As briefly set forth above in the Detailed Description, Applicant of the present disclosure performed routine NTG (N-methyl-N'-nitro-N-nitrosoguanidine) mutagenesis to create a pool of B. licheniformis mutants (i.e.. B. licheniformis daughter cells), which NTG modified daughter cells were subsequently screened to identify B. licheniformis daughter cell mutations that can increase the production of industrially relevant proteins of interest (e.g., an amylase, a protease, etc). More specifically, via routine Ceralpha a- amylase assays, Applicant identified a mutant B. licheniformis (daughter) cell comprising a SNP in a gene encoding a variant GlcT protein (i.e., allele glcTl·, SEQ ID NO: 56), which variant/? licheniformis cell was capable of producing increased amounts of heterologous amylase protein, relative to a parental B. licheniformis cell comprising a gene encoding a wild-type GlcT protein (e.g., see, Example 8 below), wherein the variant and parental cells are cultivated under identical conditions. The Ceralpha a-amylase assay, further described below in Example 8, generally involves incubating whole culture broth with a substrate mixture under defined conditions, wherein the reaction is terminated (and color developed) by the addition of a base solution (e.g., as described in PCT publication No. WO2014/164777).

[0268] Thus, as generally set forth above in the Detailed Description, a wild-type B. licheniformis glcT gene encodes a wild-type GlcT protein of SEQ ID NO: 82 (comprising a Leucine (L) at amino acid position 67 of SEQ ID NO: 82), which wild-type GlcT protein is a transcriptional anti-terminator protein (e.g., see, Schmalisch et al., 2003; Manival et al., 1997; Stulke et al, 1998; Postma et al., 1993; Stulke and Hillen, 2000; Plumbridge, 2002; Stulke et al., 1997 and Langbein et al., 1999). The mutant glcT gene (i.e., allele glcTl ; SEQ ID NO: 56) encodes a variant GlcT protein of SEQ ID NO: 55, comprising a Leucine (L) to Phenylalanine (F) amino acid substitution at amino acid position 67 (F67; SEQ ID NO: 55; e.g., see FIG. 1A and FIG. 1B).

EXAMPLE 2

CONSTRUCTION OF glcT Cas9 TARGETING VECTORS

[0269] A synthetic polynucleotide encoding the Cas9 protein from S. pyogenes (SEQ ID NO: 1), comprising an N-terminal nuclear localization sequence (NLS; “APKKKRKV”; SEQ ID NO: 2), a C-terminal NLS (“KKKKLK”; SEQ ID NO: 3) and a rieco-histidine tag (“HHHHHHHHHH”; SEQ ID NO: 4), was operably linked to the aprE promoter from B. subtilis (SEQ ID NO: 5) and amplified using Q5 DNA polymerase (NEB) per manufacturer’s instructions with the forward (SEQ ID NO: 6) and reverse (SEQ ID NO: 7) primer pair set forth below in Table 2.

TABLE 2

FORWARD AND REVERSE PRIMER PAIR [0270] The backbone (SEQ ID NO: 8) of plasmid pKB320 (SEQ ID NO: 9) was amplified using Q5 DNA polymerase (NEB) per manufacturer’s instructions with the forward (SEQ ID NO: 10) and reverse (SEQ ID NO: 11) primer pair set forth below in Table 3.

TABLE 3

FORWARD AND REVERSE PRIMER PAIR

[0271] The PCR products were purified using Zymo clean and concentrate 5 columns per manufacturer’s instructions. Subsequently, the PCR products were assembled using prolonged overlap extension PCR (POE-PCR) with Q5 Polymerase (NEB) mixing the two fragments at equimolar ratio. The POE-PCR reactions were cycled: 98°C for five (5) seconds, 64°C for ten (10) seconds, 72°C for four (4) minutes and fifteen (15) seconds for 30 cycles. Five (5) pl of the POE-PCR (DNA) was transformed into ToplO E. coli (Invitrogen) per manufacturer’s instructions and selected on lysogeny (L) Broth (Miller recipe; 1% (w/v) Tryptone, 0.5% Yeast extract (w/v), 1% NaCl (w/v)), containing fifty (50) pg/ml kanamycin sulfate and solidified with 1.5% Agar. Colonies were allowed to grow for eighteen (18) hours at 37°C. Colonies were picked and plasmid DNA prepared using Qiaprep DNA miniprep kit per manufacturer’s instructions and eluted in fifty-five (55) pl of ddfhO. The plasmid DNA was Sanger sequenced to verify correct assembly, using the sequencing primers (SEQ ID NOs: 12-20) set forth below in Table 4.

TABLE 4

SEQUENCING PRIMERS

[0272] The correctly assembled plasmid, pRF694 (SEQ ID NO: 21), was used to assemble the plasmid for the introduction of the L67F glcT mutation. More particularly, the glcT gene (SEQ ID NO: 22) of B. licheniformis contains a Cas9 target site that overlays the L67 codon (SEQ ID NO: 23). The target site can be converted into a DNA sequence encoding a variable targeting (VT) domain (SEQ ID NO: 24) by removing the PAM sequence (SEQ ID NO: 25). The DNA sequence encoding the VT domain (SEQ ID NO: 24) can be operably fused to the DNA sequence encoding the Cas9 Endonuclease Recognition domain (CER; SEQ ID NO: 26) such that when transcribed by RNA polymerase in the cell, it produces a functional gRNA (SEQ ID NO: 27). The DNA encoding the gRNA (SEQ ID NO: 28) can be operably linked to a promoter operable in Bacillus sp. cells (e.g., the rrnlp2 promoter from B. subtilis SEQ ID NO: 29) and a terminator operable in Bacillus sp. cells (e.g., the tO terminator of lambda phage; SEQ ID NO: 30), such that the promoter is positioned 5' of the DNA encoding the gRNA and the terminator is positioned 3' of the DNA encoding the gRNA, to create a gRNA expression cassette (SEQ ID NO: 31).

[0273] An editing template for creating the L67F mutation in glcT can be amplified from B. licheniformis genomic DNA (gDNA) by creating two fragments. First, the 500 bp upstream (5') of the first position of codon 67 of glcT (SEQ ID NO: 32) was amplified using Q5 DNA polymerase according to the manufacturer’s instructions and the forward (SEQ ID NO: 33) and reverse (SEQ ID NO: 34) primer pair set forth below in Table 5, wherein the reverse primer in this case contains a change to the first position of codon 67 from CTC to TTC converting codon 67 from a Leucine to a Phenylalanine.

TABLE 5

FORWARD AND REVERSE PRIMER PAIR

[0274] A second fragment containing the 500 bp downstream (3') of the first position of codon 67 of glcT (SEQ ID NO: 35) was amplified from B. licheniformis gDNA using Q5 DNA polymerase according to the manufacturer’s instructions and the forward (SEQ ID NO: 36) and reverse (SEQ ID NO: 37) primer pair set forth below in Table 6. TABLE 6

FORWARD AND REVERSE PRIMER PAIR

[0275] The DNA fragment containing the gRNA expression cassette and the two homology arms can be assembled into pRF694 using standard molecular biology techniques generating plasmid pRF731 (SEQ ID NO: 38), generating an E. coli-B. licheniformis shuttle plasmid containing a Cas9 expression cassette, a gRNA expression cassette encoding a gRNA targeting glcT and a lOOlbp glcT editing template that will create the L67F mutation in the glcT gene and obliterate glcTts 1 and alleviate Cas9 mediated cleavage of the target site.

EXAMPLE 3

GENERATION OF BACILLUS LICHENIFORMIS CELLS COMPRISING THE glcT ^L67F

MUTATION

[0276] In the present example, the pRF731 plasmid (SEQ ID NO: 38) described above was amplified using rolling circle amplification (Sygnis) for 18 hours according to manufacturer’s instructions. The rolling circle amplified pRF731 (SEQ ID NO: 38) was transformed into competent (parental) B. licheniformis cells comprising (harboring) a pBL.comK plasmid (SEQ ID NO: 50) as generally described in International PCR publication Nos. WO2017/075195, W02002/14490 and WO2008/7989. Cell/DNA transformation mixes were plated onto L-broth (Miller recipe) containing 20 pg/ml of kanamycin and solidified with 1.5% Agar. Colonies were allowed to form at 37°C. Colonies that grew on the L agar plates containing kanamycin were picked and streaked on L agar plates containing l00pg/ml spectinomycin to select for pBL.comK plasmid (SEQ ID NO: 50). The glcT locus (SEQ ID NO: 51) was amplified from transformed cells using Q5 (NEB) DNA polymerase and standard PCR reactions using the reverse (SEQ ID NO: 52) and forward (SEQ ID NO: 53) primer pair set forth below in Table 7.

TABLE 7

FORWARD AND REVERSE PRIMER PAIR

[0277] Colony PCR was performed using the following steps: (1) 98°C for 3 minutes, (2) 98°C for 5 seconds, (3) 63°C for 10 seconds, (4) 72°C for 30 seconds and (5) repeating steps 2-4 29 times, 72°C 3 minutes. Successful PCR will amplify a l,069bp polynucleotide from the glcT locus (SEQ ID NO: 50). Two (2) pl of the PCR was purified by mixing with 5m1 of Exo-SAP-IT and incubated at 37°C for 15 minutes followed by 15 minutes at 80°C. The purified PCR reactions were diluted with 40m1 of ddFTO and Sanger sequenced with the forward primer“TGAGGATCGTGAACAGATCC” (SEQ ID NO: 54).

[0278] Sequence alignments comparing the sequencing data to the WT glcT locus (SEQ ID NO: 51) revealed that some of the recovered colonies contained the desired genome edit causing the L67F mutation in the GlcT protein (SEQ ID NO: 55). A colony containing the glcT gene (SEQ ID NO: 56) encoding the L67F GlcT protein (SEQ ID NO: 55), now named allele glcTl that was still resistant to l00pg/ml spectinomycin (comprising pBL.comK) was stored as strain BF63 ( glcTl pBL.comK).

EXAMPLE 4

CONSTRUCTION OF rghR2 Cas9 TARGETING VECTORS

[0279] Plasmid pRF724 (SEQ ID NO: 39), targeting the duplication of codons 24-29 (SEQ ID NO: 40) of the B. licheniformis rghR2 gene (SEQ ID NO: 41), was created by amplifying a 8.3kb DNA fragment (SEQ ID NO: 42) from plasmid pRF694, using Q5 according to the manufacturer’s instructions and the forward (SEQ ID NO: 43) and reverse (SEQ ID NO: 44) primer pairs set forth in Table 8.

TABLE 8

FORWARD AND REVERSE PRIMER PAIR

[0280] A synthetic DNA fragment (SEQ ID NO: 45) containing the rghR2 editing template (SEQ ID NO: 46), the rrnlp2- gRNA expression cassette (SEQ ID NO: 47) was ordered from IDT and amplified using Q5 DNA polymerase and standard PCR techniques, using the forward (SEQ ID NO: 48) and reverse (SEQ ID NO: 49) primer pairs set forth in Table 9.

TABLE 9

FORWARD AND REVERSE PRIMER PAIR

[0281] The editing template gRNA expression cassette fragment (SEQ ID NO: 47) comprised 5' and 3' homology to the fragment amplified from pRF694 (SEQ ID NO: 42). The two parts were assembled using prolonged overlap extension PCR, and transformed into E. coli. A sequence verified isolate was stored as plasmid pRF724 (SEQ ID NO: 39).

EXAMPLE 5

GENERATION OF BACILLUS LICHENIFORMIS CELLS COMPRISING THE rghR2 _rest

ALLELE

[0282] Plasmid pRF724 (SEQ ID NO: 39) was amplified using rolling circle amplification (RCA) (Sygnis) for 18 hours according to the manufacturer’s instructions. The rolling circle amplified pRF724 (SEQ ID NO: 39) was transformed into competent (parental) B. licheniformis cells comprising (harboring) a pBL.comK plasmid (SEQ ID NO: 50), as generally described in International PCR publication Nos. WO2017/075195, W02002/14490 and WO2008/7989. Cell/DNA transformation mixes were plated onto L-broth (miller) containing twenty (20) pg/ml of kanamycin and solidified with 1.5% (w/v) agar. Colonies were allowed to form at 37°C.

[0283] Colonies that grew on L agar containing kanamycin were picked, streaked onto agar plates containing one-hundred (100) pg/ml spectinomycin to select for plasmid pBL.comK (SEQ ID NO: 50). The rghR2 locus (SEQ ID NO: 57) was amplified from transformants using Q5 DNA polymerase (NEB) and standard PCR reactions, using the forward (SEQ ID NO: 58) and reverse (SEQ ID NO: 59) primer pairs set for in Table 10.

TABLE 10

FORWARD AND REVERSE PRIMER PAIR

[0284] The PCR cycles were performed as described in Example 4, wherein the PCR reaction amplified the rghR2 locus (SEQ ID NO: 57). The PCR product was purified as described in Example 4, and sequenced using the method of Sanger with the sequencing primer (SEQ ID NO: 60) set forth in Table 11.

TABLE 11

SEQUENCING PRIMER

[0285] Sequencing alignments comparing the data to the parental rghR2 locus (SEQ ID NO: 57), revealed that a majority of the recovered colonies contained the rghR2 _rest allele (SEQ ID NO: 61) comprising the deletion of the tandem duplication of codons 24-29 (SEQ ID NO: 40). A colony containing the rghR2 _rest allele that was still resistant to one hundred (100) pg/ml of spectinomycin (comprising pBL.comK), was stored as strain BF62 ( rghR2 _rest pBL.comK).

EXAMPLE 6

GENERATION OF B. LICHENIFORMIS CELLS

COMPRISING rghR2 _rest AND glcTl ALLELES

[0286] Plasmid pRF724 (SEQ ID NO: 39) was amplified using RCA (Sygnis) for 18 hours according to the manufacturer’s instructions. The rolling circle amplified pRF724 (SEQ ID NO: 39) was transformed into competent BF63 ( glcTl ) B. licheniformis cells (see. Example 3) comprising (harboring) a pBL.comK (SEQ ID NO: 50) plasmid. Cell/DNA transformation mixes were plated onto L-broth (miller) containing twenty (20) pg/ml of kanamycin and solidified with 1.5% (w/v) agar. Colonies were allowed to form at 37°C.

[0287] Colonies that grew on L agar containing kanamycin were picked, streaked onto agar plates containing one hundred (100) pg/ml spectinomycin. The rghR2 locus (SEQ ID NO: 57) was amplified from transformants using Q5 DNA polymerase (NEB) and standard PCR reactions, using the forward (SEQ ID NO: 58) and reverse (SEQ ID NO: 59) primer pair set forth in Table 12.

TABLE 12

FORWARD AND REVERSE PRIMER PAIR

[0288] The PCR cycles were performed as described in Example 4, wherein the PCR reaction amplified the rghR2 locus (SEQ ID NO: 57). The PCR product was purified as described in Example 4, and sequenced using the method of Sanger with the sequencing primer (SEQ ID NO: 60) set forth in Table 13.

TABLE 13

SEQUENCING PRIMER

[0289] Sequencing alignments comparing the data to the parental rghR2 locus (SEQ ID NO: 57) revealed that a majority of the recovered colonies contained the rghR2 _rest allele (SEQ ID NO: 61), comprising the deletion of the tandem duplication of codons 24-29 (SEQ ID NO: 40). A colony containing the rghR2 _rest allele (SEQ ID NO: 61) that was still resistant to one hundred (100) pg/ml of spectinomycin (comprising pBL.comK), was stored as strain BF169 (Host rghR2 _rest glcTl pBL.comK).

EXAMPLE 7

INSERTION OF A HETEROLOGOUS AMYLASE EXPRESSION CASSETTE INTO PARENTAL AND MODIFIED B. LICHENIFORMIS CELLS BF62, BF63 AND BF169

[0290] In the present example, Applicant introduced heterologous a-amylase expression cassettes into parental and modified B. licheniformis cells BF62, BF63 and BF169. More specifically, the a-amylase expression cassettes described below were introduced into parental and modified B. licheniformis cells BF63, BF62 and BF169, wherein modified B. licheniformis (daughter) cell “BF63” comprises the introduced allele g/c ^' /Ί (i.e.. encoding the variant GlcT protein), modified B. licheniformis (daughter) cell“BF62” comprises the restored rghr2 gene ( rghr2 _KSi ), and modified B. licheniformis (daughter) cell “BF169” comprises both the introduced allele glcTl and the restored ( rghr2 _KSi ) gene, as presented below in Table 14.

TABLE 14

B. LICHENIFORMIS (DAUGHTER) CELL MODIFICATIONS

[0291] More particularly with regard to the heterologous a-amylase expression cassettes, Applicant further tested the effects of modified 5' untranslated region (mod-5 '-UTR) sequences on expression of genes encoding proteins of interest in Bacillus cells, by creating a-amylase expression cassettes comprising either the wild-type B. subtilis aprE 5'-UTR (WT-5'-UTR; SEQ ID NO: 62) or a modified 5'-UTR (mod-5'-UTR; SEQ ID NO: 63). Thus, the instant example describes the creation of Bacillus host cells for the assessment of various (modified) 5 '-UTR constructs, and their impact/influence on the production of proteins of interest when such modified 5'-UTR constructs are operably linked to an upstream (5') promoter and a downstream (3') open reading frame encoding the protein of interest.

[0292] Thus, in the present example, parental B. licheniformis cells and modified B. licheniformis (daughter) cells BF62, BF63, and BF169 (Table 14), comprising a plasmid carrying a xylose -inducible comK expression cassete (SEQ ID NO: 50), were grown overnight at 37°C and 250 RPM in fifteen (15) ml of L broth (1% (w/v) Tryptone, 0.5% Yeast extract (w/v), 1% NaCl (w/v)), containing one hundred (100) pg/ml spectinomycin dihydrochloride in a 125 ml baffled flask. The overnight culture was diluted to 0.7 (Oϋboo units) in 25 ml fresh L broth containing one hundred (100) pg/ml spectinomycin dihydrochloride in a two hundred fifty (250) ml baffle flask. Cells were grown for one (1) hour at 37°C (250 RPM). D- xylose was added to 0.1% (w/v) from a 50% (w/v) stock. Cells were grown for an additional four (4) hours at 37°C (250 RPM) and pelleted at 1700 x g for seven (7) minutes.

[0293] The cells were resuspended in one fourth (¼) volume of original culture using the spent medium. One hundred (100) pi of concentrated cells were mixed with approximately one (1) pg of either the wild- type (WT) 5 '-UTR expression construct (WT-5'-UTR; SEQ ID NO: 64) or the modified 5 '-UTR expression construct (mod-5'-UTR; SEQ ID NO: 65). For example, each expression cassete comprised (in the 5' to 3' direction) the same 5' catH homology arm (SEQ ID NO: 66), catH gene (SEQ ID NO: 67) and spoVGrrnlp hybrid promoter (SEQ ID NO: 68), operably linked to either the wild-type B. subtilis aprE 5'- UTR (SEQ ID NO: 62) or the modified aprE 5'-UTR (SEQ ID NO: 63). In addition, the 5'-UTR was operably linked to the DNA encoding the lat signal sequence (SEQ ID NO: 69), followed by DNA (ORF) encoding variant G. stearothermophilus a-amylase (SEQ ID NO: 70). The 3' end of the DNA (ORF) encoding the variant G. stearothermophilus a-amylase (SEQ ID NO: 70), was operably linked to the lat terminator (SEQ ID NO: 71), which was operably linked to the 3' catH homology arm (SEQ ID NO: 72). Transformation reactions were incubated at 37°C, 1000RPM for approximately ninety (90) minutes.

[0294] Transformation mixes were plated on peti plates filled with L-broth containing ten (10) pg/ml chloramphenicol solidified with 1.5% (w/v) agar. Plates were incubated at 37°C for two (2) days. Colonies were streak purified on peti plates filled with L-broth containing 1% (w/v) insoluble com starch solidified with 1.5% (w/v) agar. Plates were incubated at 37°C for twenty -four (24) hours until colonies had formed. Starch hydrolysis was indicated by clearing of the insoluble starch surrounding the colony, forming a halo, and was used to select transformants expressing variant G. stearothermophilus a-amylase protein (SEQ ID NO: 73). Colony PCR was used to amplify the catH locus (WT construct, SEQ ID NO: 74; modified construct, SEQ ID NO: 75) from halo producing colonies using standard techniques, and the forward (SEQ ID NO: 76) and reverse (SEQ ID NO: 77) primer pairs set forth in Table 15. TABLE 15

FORWARD AND REVERSE PRIMER PAIR

[0295] PCR products were purified from excess primers and nucleotides using standard techniques and sequenced using the method of Sanger and the sequencing primers set forth in Table 16.

TABLE 16

SEQUENCING PRIMERS

[0296] Sequence verified B. licheniformis (daughter) cells comprising the WT-5'-UTR expression cassette (SEQ ID NO: 64) or sequence verified B. licheniformis (daughter) cells comprising the modified-5 '-UTR (mod-5'-UTR) expression cassette (SEQ ID NO: 65) were stored as shown in Table 17.

TABLE 17

PARENTAL AND MODIFIED B. LICHENIFORMIS CELLS COMPRISING EITHER WT-5 - UTR EXPRESSION CASSETTE OR MOD-5 -UTR EXPRESSION CASSETTE

EXAMPLE 8

PRODUCTION OF AMYLASE ENZYME IN MODIFIED B. LICHENIFORMIS CELLS [0297] In the present example, modified B. licheniformis cells comprising the (mutant) allele glcTl (SNP C199T) encoding the variant GlcT protein (i.e.. L67F substitution) and wild-type (parental) B. licheniformis cells were struck on Luria agar plates supplemented with 1% insoluble starch. More particularly, the parental and modified B. licheniformis (daughter) cells set forth in Table 18 were transformed with an amylase construct described above in Example 7, Table 17 (i.e., WT-5'-UTR expression cassette SEQ ID NO: 64 or mod-5'-UTR expression cassette SEQ ID NO: 65) were tested and stored as shown in Table 18.

TABLE 18

B. LICHENIFORMIS HOST CELLS SCREENED

[0298] More specifically, a clearing zone, indicative of amylolytic activity, was clearly visible around the colonies comprising the amylase expression cassette integrated. Thus, the production of the amylase by B. licheniformis cells was experimentally tested by growing the cells in micro titer plates, using a MOPS base medium MBD medium, prepared essentially as known in the art (see. Neidhardt et al, 1974), except that NH4CI2, FeSO _t , and CaCh were omitted from the base medium, three (3) mM K2HPO4 was used, and the base medium was supplemented with sixty (60) mM urea, seventy-five (75) g/L glucose, and one percent (1%) soytone. The micronutrients were made up as a 100X stock solution in one liter, 400 mg FeS04 7H ₂ 0, 100 mg MnS0 ₄ H ₂ 0, 100 mg ZnS0 ₄ 7H ₂ 0, 50 mg CuCl ₂ 2H ₂ 0, 100 mg C0CI2 6H ₂ 0, 100 mg NaMo04 2H2O, 100 mg Na2B407 IOH2O, 10 ml of 1M CaCh, and 10 ml of 0.5 M sodium citrate. CaCh was added to five (5) mM, and pH was adjusted to 6.8.

[0299] After seventy (70) hours of growth in an Infors incubator (37°C, 270 rpm), the amylase enzyme concentration in the whole cell broth was determined using the a- Amylase Ceralpha Assay Kit (Megazyme, Wicklow, Ireland). The Ceralpha a-amylase assay involves incubating whole culture broth with a substrate mixture under defined conditions, and the reaction is terminated (and color developed) by the addition of a base solution. The substrate is a mixture of the defined oligosaccharide“nonreducing-end blocked p- nitrophenyl maltoheptaoside” (“BPNPG7” substrate), and excess levels of glucoamylase and b-glucosidase (which have no action on the native substrate due to the presence of the“blocking group”) . Upon hydrolysis of the oligosaccharide by endo-acting a-amylase (or C6 amylase), the excess quantities of a-glucosidase and glucoamylase present in the mixture give instantaneous and quantitative hydrolysis of the /7-nitrophcnyl maltosaccharide fragment to glucose and free /;-nitrophenol. The absorbance at 405 nm is measured, and relates directly to the level of amylase in the sample analyzed. The equipment used for this set of assays includes a Biomek FX Robot (Beckman Coulter); a SpectraMAX MTP Reader (type 340-Molecular Devices) and iEMS incubator/shaker (Thermo Scientific). In this assay system, the reagent and solutions used were: (1) / nitrophcnyl maltoheptaoside (BPNPG7) substrate (Megazyme Ceralpha kit); (2) Dilution buffer: 50 mM MOPS, 0.1 mM CaCl2, 0.005% TWEEN ^® 80 buffer, pH 7.15; and (3) 200 mM Boric acid / NaOH buffer, pH 10.2 (STOP buffer).

[0300] Thus, a vial containing 54.5 mg BPNPG7 substrate was dissolved in ten (10) ml of milliQ water. The amylase samples (whole cell broth) were diluted 1600X with dilution buffer. The assay was performed by adding twenty-five (25) pl of diluted amylase solution into the wells of a MTP, followed by the addition of thirty-five (35) mΐ of the 5.45 mg/ml BPNPG7 substrate solution. The solutions were mixed and the MTP was sealed with a plate seal, and placed in an incubator/shaker (iEMS- Thermo Scientific) for eight (8) minutes at 25°C. The reaction was terminated by adding one hundred (100) mΐ STOP buffer and the absorbance was read at 405 nm in an MTP-Reader. A non-enzyme control was used to correct for background absorbance values. To calculate the variant amylase enzyme concentration (mg/L), a dilution series of purified variant amylase enzyme standard control sample was incorporated into the experiment.

[0301] The amylase activity and specific productivity of the amylase are shown in FIG. 2A and FIG. 2B, respectively. For example, as presented in FIG. 2B, the normalized specific productivity of the BF134 cells (BF134: WT-5'-UTR and WT-GlcT) relative to the BF117 cells (BF117: mod-5'-UTR and WT-GlcT ) indicates a similar amylase productivity. In contrast, as presented in FIG. 2B, the normalized specific productivity of the HM151 cells (HM151 : WT-5'-UTR and allele GlcTl) relative to the BF134 cells or BF117 cells (i.e., both BF134 and BF117 cells comprising a wild-type GlcT gene) indicates an approximate 5% increase in specific productivity of the HM151 cells, thereby demonstrating that modified Bacillus cells comprising allele glcTl are capable of producing increased amounts of a protein of interest relative to Bacillus cells comprising a native, wild-type glcT gene.

[0302] Furthermore, a presented in FIG. 2B, the normalized specific productivity of the HM150-1 cells (HM150-1 : mod-5'-UTR and allele GlcTl) relative to the BF134 cells or BF117 cells (i.e., comprising a wild-type GlcT gene) indicates an approximate 9% increase in specific productivity of the HM150-1 cells, further demonstrating that modified Bacillus cells comprising allele glcTl are capable of producing increased amounts of a protein of interest relative to Bacillus cells comprising a wild-type glcT gene. Fikewise, the normalized specific productivity of the HM150-1 cells (HM150-1 : mod-5'-UTR and allele GlcTl) relative to the HM151 cells (HM151 : WT-5'-UTR and allele GlcTl) indicates an approximate 4% increase in specific productivity of the HM150-1 relative to the HM151 cells, which demonstrates that “mod-5 '-UTR” sequence present in the amylase construct further contributes to the observed increase in specific productivity of the HM150-1 cells. EXAMPLE 9

ALPHA-AMYLASE PRODUCTION AT SMALL SCALE

[0303] In the present example four Bacillus host strains named BF118, BF165, BF171 and BF260, comprising an a-amylase expression cassette with either the WT-5'-UTR (SEQ ID NO: 64) or the mod-5' UTR (SEQ ID NO: 65), were assessed for a-amylase production under small scale conditions. The four strains were streak purified on L agar plates containing 1% (wv ^-1 ) insoluble starch and grown for approximately twenty-four (24) hours at 37°C. A single halo positive colony was inoculated into 15 ml of Tryptic Soy Broth (1.7% (wv ¹ ) Tryptone, 0.3% (wf ¹ ) soytone, 0.25% (wv ¹ ) glucose, 0.5% (wv ¹ ) sodium chloride, 0.25% (wv ¹ ) Dipotassium phosphate) and grown at 37°C (250 RPM) for 6 hours. Subsequently, 0.025 ml of this seed culture was inoculated into 25 ml of flask growth medium (4% (wv ¹ ) MES, 0.1% (wv ¹ ) Monopotassium phosphate, 0.05% (wv ¹ ) sodium chloride, 0.03% (wv ¹ ) soytone, containing trace metals, pH 6.8 with Ammonium hydroxide). A single high glucose release feed bead (Kuhner) was added (feed rate 57 mg/L.hr). The cultures were grown at 42°C (250 RPM) for 90 hours. The total secreted protein production was determined using the method of Bradford with a BSA standard. The relative a-amylase production averaged from repeat measurements of at least two independent flasks for each strain is shown in Table 19 below.

TABLE 19

SMALL SCALE PRODUCTION OF a-AMYLASE

[0304] Thus, as presented in Table 19, the Bacillus host cells BF171 and BF260 (comprising a restored rghR2 gene ( rghR2 _rest ) and allele glcTl) demonstrate an approximately 9% increase in relative a-amylase production when compared (vis-a-vis) to Bacillus host cells BF118 and BF169 (comprising a restored rghR2 gene ( rghR2 _rest ) and a wild-type glcT gene). REFERENCES

PCT International Publication No. WO 1989/06279

PCT International Publication No. WO 1999/20726

PCT International Publication No. WO 1999/20769

PCT International Publication No. WO 1999/20770

PCT International Publication No. W02002/14490

PCT International Publication No. W02003/083125

PCT International Publication No. W02003/089604

PCT International Publication No. W02008/024372

PCT International Publication No. W02009/149130

PCT International Publication No. WO2014/164777

U.S. Patent No. 4,914,031

U.S. Patent No. 4,980,288

U.S. Patent No. 5,208, 158

U.S. Patent No. 5,310,675

U.S. Patent No. 5,336,611

U.S. Patent No. 5,399,283

U.S. Patent No. 5,441,882

U.S. Patent No. 5,482,849

U.S. Patent No. 5,631,217

U.S. Patent No. 5,665,587

U.S. Patent No. 5,700,676

U.S. Patent No. 5,741,694

U.S. Patent No. 5,858,757 U.S. Patent No. 5,880,080

U.S. Patent No. 6,197,567

U.S. Patent No. 6,218,165

U.S. Patent Publication No. 2014/0329309

U.S. RE 34,606

Albertini and Galizzi. Bacieriol., 162:1203-1211, 1985.

Bergmeyer et al, "Methods of Enzymatic Analysis" vol. 5, Peptidases, Proteinases and their Inhibitors, Verlag Chemie, Weinheim, 1984.

Botstein and Shortle, Science 229: 4719, 1985.

Brode et al, “Subtilisin BPN' variants: increased hydrolytic activity on surface-bound substrates via decreased surface activity”, Biochemistry, 35(10):3162-3169, 1996.

Caspers et al,“Improvement of Sec-dependent secretion of a heterologous model protein in Bacillus subtilis by saturation mutagenesis of the N-domain of the AmyE signal peptide”, Appl. Microbiol. Biotechnol, 86(6) : 1877-1885, 2010.

Chang et al, Mol. Gen. Genet., 168:11-115, 1979.

Christianson et al, Anal. Biochem., 223:119 -129, 1994.

Devereux et a/., Nucl. Acid Res., 12: 387-395, 1984.

Earl et al,“Ecology and genomics of Bacillus subtilis”, Trends in Microbiology., 16(6):269-275, 2008. Ferrari et al, "Genetics, " in Harwood et al. (ed.), Bacillus, Plenum Publishing Corp., 1989.

Fisher et. al, Arch. Microbiol., 139:213-217, 1981.

Guerot-Fleury, Gene, 167:335-337, 1995.

Hamoen et al,“Controlling competence in Bacillus subtilis: shared used of regulators”, Microbiology, 149:9-17, 2003.

Hamoen et al, Genes Dev. 12: 1539- 1550, 1998.

Hampton et al, Seroloaical Methods, A Laboratory Manual, APS Press, St. Paul, MN, 1990.

Hardwood and Cutting (cds.) Molecular Biological Methods for Bacillus, John Wiley & Sons, 1990. Hayashi et al, Mol. Microbiol., 59(6): 1714-1729, 2006 Higuchi et al, Nucleic Acids Research 16: 7351, 1988.

Ho et al, Gene 77: 61, 1989.

Hoch et al, J. Bacteriol, 93:1925 -1937, 1967.

Holubova. h ^' oha Microbiol, 30:97, 1985.

Hopwood, The Isolation of Mutants in Methods in Microbiology (J. R. Norris and D. W. Ribbons, eds.) pp 363-433, Academic Press, New York, 1970.

Horton et al, Gene 77: 61, 1989.

Hsia et al, Anal Biochem., 242:221-227, 1999.

Iglesias and Trautner, Molecular General Genetics 189: 73-76, 1983.

Jensen et al,“Cell-associated degradation affects the yield of secreted engineered and heterologous proteins in the Bacillus subtilis expression system” Microbiology, 146 (Pt 10:2583-2594, 2000.

Langbein et al, J. Mol. Biol., 293, 795-805, 1999.

Liu and Zuber, 1998,

Lo et al, Proceedings of the National Academy of Sciences USA 81 : 2285, 1985.

Maddox et al, J. Exp. Med., 158:1211, 1983.

Manival et al, EMBO J, 16, 5019-5029, 1997.

Mann et al, Current Microbiol., 13:131 -135, 1986.

McDonald, ./ Gen. Microbiol. , 130:203, 1984.

Needleman and Wunsch, J. Mol. Biol., 48: 443, 1970.

Neidhardt et al, Culture medium for enterobacteria . J. Bacteriol., 119(3):736-747, 1974.

Ogura & Fujita, FEMS Microbiol Lett., 268(1): 73-80. 2007.

Olempska-Beer et al,“Food-processing enzymes from recombinant microorganisms— a review”’ Regul. Toxicol. Pharmacol., 45(2): 144-158, 2006.

Palmeros et al, Gene 247:255 -264, 2000.

Parish and Stoker, FEMS Microbiology Letters 154: 151-157, 1997.

Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85: 2444, 1988. Perego, 1993, In A. L. Sonneshein, J. A. Hoch, and R. Losick, editors, Bacillus subtilis and Other Gram- Positive Bacteria, Chapter 42, American Society of Microbiology, Washington, D.C.

Plumbridge, Curr. Opin. Microbiol. 5, 187-193, 2002.

Postma et al, Microbiol. Rev. 57, 543-594, 1993.

Raul et at,“Production and partial purification of alpha amylase from Bacillus subtilis (MTCC 121) using solid state fermentation”, Biochemistry Research International, 2014.

Sarkar and Sommer, BioTechniques 8: 404, 1990.

Saunders et at, J. Bacteriol., 157:718-726, 1984.

Schmalisch et al.,“Control of the Bacillus subtilis Antiterminator Protein GlcT by Phosphorylation; Elucidation of The Phosphorylation Chain Leading To Inactivation Of Glcf JBC, 278 (51), 51108-51115, 2003.

Shimada. Meih. Mol. Biol. 57: 157; 1996

Smith and Waterman, Adv. Appl. Math., 2: 482, 1981.

Smith et at, Appl. Env. Microbiol., 51 :634 1986.

Stahl and Ferrari, J. Bacteriol, 158:411-418, 1984.

Stahl et al, J. Bacteriol., 158 :411-418, 1984.

Stulke and Hillen. Annu. Rev. Microbiol., 54, 849-880, 2000.

Stulke et at, Mot Microbiol. 28, 865-874, 1998.

Stulke et at, Mot Microbiol., 25, 65-78, 1997.

Tarkinen, et al, J. Biol. Chem. 258: 1007-1013, 1983.

Trieu-Cuot et at, Gene, 23:331-341, 1983.

Van Dijl and Hecker,“Bacillus subtilis: from soil bacterium to super-secreting cell factory . Microbial Cell Factories, 12(3). 2013.

Vorobjeva et at, FEMS Microbiol. Lett., 7:261-263, 1980.

Ward, "Proteinases, " in Fogarty (ed.)., Microbial Enzymes and Biotechnology. Applied Science, London, pp 251-317, 1983.

Wells et at, Nucleic Acids Res. 11 :7911-7925, 1983. Westers etal.,“ Bacillus subtilis as cell factory for pharmaceutical proteins: a biotechnological approach to optimize the host organism”, Biochimica et Biophysica Acta. , 1694:299-310, 2004.

Yang et al, J. Bacteriol.,160: 15-21, 1984.

Yang et al, Nucleic Acids Res. 11: 237-249, 1983.

Youngman et at, Proc. Natl. Acad. Sci. USA 80: 2305-2309, 1983.